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ABSTRACT 
 
Red blood cells (RBCs) are a-nucleated cells particularly exposed to different 
stimuli, among which circulating hormones and intra/extra-cellular derivatives 
from oxidization processes. In addition, our previous studies showed that in the 
case of inflammatory diseases with GSH content alterations, RBCs were much 
more sensitive to diamide, a mild oxidant able to trigger tyrosine-phosphorylation 
(Tyr-P) of membrane proteins, mainly band 3.  
Aldosterone (Aldo), mineralocorticoid hormone, has been shown to induce many 
effects other than the common diuretic process regulation and involving the 
expression and activation of the superoxide generating enzyme NADPH oxidase, 
thus potentially explaining the increased plasma markers of oxidative stress (OS) 
like isoprostanes in primary aldosteronism (PA), disease characterized by 
excessive Aldo secretion. This well-known Aldo action is mediated by the 
activation of a cytosolic specific receptor, the mineralocorticoid receptor (MR), in 
the so called genomic pathway, which distinguishes from the direct effect of Aldo 
on many proteins and enzymes in the second mechanism, also known as non-
genomic pathway. 
Starting from these evidences, if a direct Aldo involvement in the triggering of 
inflammatory-related oxidative status of the cells was evolving, RBCs were the 
eligible cells for the investigation of the non-genomic Aldo pathway. 
The study involved PA patients and healthy control (HC) and consisted with three 
phases: i) a first approach was carried out to evidence potential alterations in PA 
RBCs followed by an in vitro deepening to assess the effective direct/indirect 
involvement of Aldo in these alterations; ii) once identified as responsible of the 
RBCs alterations found in PA, Aldo pathway within HC RBCs cytosol was 
investigated; iii) at last, Aldo-related pathway in RBCs was studied with particular 
attention to the mechanism leading to membrane band 3 alterations starting from 
Aldo induced receptor activation. 
In the first part, PA RBCs were showed to have oxidative-like alterations such as 
band 3 protein increase of both Tyr-P level and clustering, thus suggesting that PA 
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could be linked to other inflammatory diseases. The effects of Aldo, cortisol 
(Cort) and canrenone (Can) (added as agonist and inhibitor, respectively) were 
compared and Aldo was confirmed as the only responsible of the alterations 
previously observed in PA RBCs. Furthermore, Aldo was shown to trigger RBCs 
membrane alterations leading to autologous IgG binding in a sort of premature 
ageing of the cells. 
The second part of the study analyzed the mechanism of Aldo action: for the first 
time MR was identified in RBCs cytosol as a soluble multi-protein complex, 
differently regulated by the effector utilized. In facts, in the presence of Aldo, MR 
broke away from the complex to form dimers which were promptly proteolysed in 
a sort of turn off signaling. Can or Cort were not able to trigger similar events, 
thus explaining the different alterations found on RBCs membranes. 
However, since to now no direct evidence was found about the possibility that 
Aldo induced an increase of oxidation status in RBCs, oxidization level in both 
membranes and cytosol was addressed in the third and last part of the study. 
Results showed no difference in GSH and GSSP contents and carbonic anhydrase 
(CA) monomerization and activity between HC and PA RBCs. In contrast, 
preliminary data would confirm a sort of oxidative-related increase of band 3 
disulfide bond formation, thus suggesting a new intriguing mechanism leading to 
band 3 increased oxidative status without changing the common anti-oxidative 
cellular defenses. Further investigations addressing this mechanism are in 
progress. 
In conclusion, we found that in PA RBCs Aldo is responsible for the membrane 
alterations leading to a potential premature removal of the cells from circulation. 
Aldo exerts its effect through the activation of the soluble MR complex, which 
participates in the modulation of the Aldo signaling through the possibility of 
being differently affected by other steroids or Aldo inhibitors (Can). Further 
studies are in progress to explore both nature and potential mediators of the Aldo-
induced alterations in the band 3 dimer formation. 
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RIASSUNTO 
 
Gli eritrociti (RBCs) sono cellule non nucleate particolarmente esposte a differenti 
stimoli, tra i quali l’effetto degli ormoni circolanti nel sangue e i derivati dei 
processi di ossidazione intra o extracellulari. Studi precedenti condotti nel nostro 
laboratorio hanno dimostrato che, nel caso di malattie infiammatorie con 
alterazione del contenuto di GSH rispetto ai controlli, gli eritrociti erano molto più 
sensibili alla diamide, un blando ossidante in grado di innescare la tirosin-
fosforilazione (Tyr-P) delle proteine di membrana, principalmente della proteina 
banda 3. 
L’aldosterone (Aldo), ormone mineralocorticoide, oltre alla sua classica azione 
regolatoria dei processi diuretici, è in grado di indurre molti altri effetti tra i quali 
l’espressione e l’attivazione dell’enzima NADPH ossidasi, generatore di anione 
superossido. Questo fatto potrebbe potenzialmente spiegare l’incremento di 
marker plasmatici di stress ossidativo (OS) come gli isoprostani, 
nell’aldosteronismo primitivo (PA), patologia caratterizzata da un’eccessiva 
secrezione di Aldo. 
Partendo da queste evidenze, gli RBCs erano cellule ottimali per studiare se 
l’Aldo potesse indurre un aumentato stato di ossidazione determinato da una sua 
azione diretta sui processi infiammatori. Infatti, in queste cellule non nucleate, un 
eventuale coinvolgimento dell’Aldo nei meccanismi infiammatori, mediante 
un’azione non-genomica, sarebbe stato univocamente dimostrato. 
Lo studio ha coinvolto sia pazienti con PA che controlli sani (HC) e si è svolto in 
tre fasi: i) in un approccio iniziale abbiamo valutato se esistessero potenziali 
alterazioni negli RBCs dei pazienti, procedendo, poi, con un approfondimento in 
vitro condotto sugli RBCs di HC per confermare o meno un diretto 
coinvolgimento dell’Aldo nell’indurre queste alterazioni; ii) una volta identificato 
come responsabile effettivo delle alterazioni riscontrate, abbiamo cercato di 
chiarire il meccanismo di azione dell’Aldo a livello citosolico; iii) infine, partendo 
dall’evidenza che l’azione dell’Aldo veniva mediata dall’attivazione del recettore 
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citosolico, abbiamo cercato di capire il meccanismo attraverso cui questa 
attivazione si trasmettesse, a livello delle membrane. 
Nella prima parte, abbiano dimostrato che negli RBCs dei pazienti erano presenti 
delle alterazioni quali un incremento sia della Tyr-P della banda 3 che una sua 
aggregazione, suggerendo, così, che la patologia potesse essere correlata ad uno 
stress ossidativo come dimostrato in altre malattie infiammatorie. Inoltre, dopo 
aver comparato gli effetti di Aldo, cortisolo (Cort) e canrenone (Can) (aggiunti 
rispettivamente come agonista ed inibitore), abbiamo confermato che era proprio 
l’Aldo il diretto responsabile delle alterazione che, in ultima, portavano ad un 
aumento della quantità degli anticorpi autologhi legati alla membrana, 
rispecchiando una prematuro invecchiamento cellulare.  
Nella seconda parte dello studio, abbiamo dimostrato, per la prima volta, la 
presenza a livello citosolico del recettore dei mineralocorticoidi (MR), che risulta 
essere presente in un complesso multi-proteico di elevato peso molecolare. 
Inoltre, abbiamo evidenziato come solo l’Aldo inducesse la liberazione dell’MR 
dal complesso a formare dimeri prontamente proteolizzati in una sorta di 
spegnimento del segnale. Al contrario, né Cort né Can erano in grado di indurre 
l’attivazione del recettore. 
Tuttavia, poiché finora non è mai stato dimostrato se l’Aldo potesse indurre un 
aumento delle stato ossidativo dell’eritrocita, nella terza parte dello studio 
abbiamo analizzato alcuni markers di ossidazione sia a livello di membrana che di 
citosol. I nostri risultati indicano che nessuna modifica del contenuto di GSH o di 
proteine glutationilate (GSSP) era presente nei pazienti rispetto ai controlli, come 
nessuna alterazione nella monomerizzazione e attivazione della anidrasi carbonica 
(CA), nuovo parametro nella valutazione di un aumentato stato di ossidazione. 
Tuttavia, i nostri risultati mostrano che la proteina banda 3 risulta effettivamente 
sottoposta ad uno stress ossidativo che ne induce l’aggregazione attraverso la 
formazione di ponti disolfuro. Risultato, questo, che merita ulteriori indagini ed 
approfondimenti. 
In conclusione, abbiamo trovato che negli RBCs dei pazienti con PA l’Aldo è 
responsabile di alterazioni di membrana che portano ad una potenziale prematura 
rimozione delle cellule dalla circolazione. L’azione dell’Aldo viene mediata a 
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livello citosolico dall’MR, ma non dal Cort. Ulteriori studi sono in corso per 
esplorare sia la natura che il meccanismo di potenziali mediatori dell’effetto 
dell’Aldo-MR a livello delle membrane eritrocitarie. 
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INTRODUCTION 
 
1. HUMAN RED BLOOD CELLS 
Red blood cells (RBCs), also called erythrocytes, are the most common type of 
blood cell. During their lifetime, RBCs travel through blood vessels of various 
sizes, taking up oxygen in the lungs and releasing it into tissues while undergoing 
large passive deformations during repeated passage through the narrow capillaries 
of the microvasculature (Mohandas and Gallagher, 2008). Human RBCs take on 
average 20 seconds to complete one cycle of circulation. Survival of practically all 
other cells in the body depends upon the proper functioning of RBCs. 
In humans, mature RBCs are non-nucleated cells, flexible and oval biconcave 
disks with a diameter of approximately 6.2–8.2 µm and a thickness at the thickest 
point of 2–2.5 µm and a minimum thickness in the center of 0.8–1 µm, being 
much smaller than most other human cells.  
 
Figure 1. Schematic representation of red blood cell. 
 
A normal RBC is a biconcave disk to achieve a maximum surface area to 
cytoplasmic volume ratio. 
The cytoplasm of RBCs is rich in hemoglobin (Hb), an iron-containing 
biomolecule that can bind oxygen and is responsible for the red color of the cells. 
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The cell membrane is composed of proteins and lipids, and this structure provides 
properties essential for physiological cell function such as deformability and 
stability while traversing the circulatory system and specifically the capillary 
network. 
Mature RBCs in mammals lack a cell nucleus and most organelles, in order to 
accommodate maximum space for Hb. The cells develop in the bone marrow and 
circulate for about 100–120 days in the body before their components are recycled 
by macrophages. 
 
1.1. Life cycle of RBCs 
Human RBCs are produced through a process named erythropoiesis, developing 
from stem cells to mature erythrocytes in about 7 days. Through this process 
RBCs are continuously produced in the red bone marrow of large bones and this 
production can be stimulated by the hormone erythropoietin (EPO), synthesized 
by the kidney. Normal adult humans produce and release into the circulation 
approximately 2×10
11
 new RBCs each day. The newly produced cells have 
extruded their nuclei in the bone marrow before they are released into the blood. 
However, these cells are irregularly shaped, have residual surface proteins of 
erythroblasts, and retain internal organelles including ribosomes, endoplasmic 
reticulum and mitochondria. Circulating reticulocytes are from 24 to 35% larger 
than the other erythrocytes in the blood so that during their 1–2 day maturation 
they lose about one-quarter of their volume and the residual internal organelles are 
degraded by multiple cellular processes including proteasomal degradation, 
autophagy, and vesicle exocytosis. Once a reticulocyte matures into a biconcave 
RBC, it will normally circulate for more than 110-120 days, but it will gradually 
lose about another 20% of its membrane and associated cytoplasm through 
exocytosis of vesicles that contain concentrated amounts of chemically modified 
Hb, including oxidized and glycated forms. (Koury, 2014) 
At the end of their lifespan, they become senescent, and are removed from 
circulation. The aging RBCs undergoes changes in its plasma membrane, making 
it susceptible to selective recognition by macrophages and subsequent 
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phagocytosis in the mononuclear phagocyte system. This process is termed 
eryptosis and normally occurs at the same rate of production by erythropoiesis. 
(Lang and Qadri, 2012) 
The spleen filters a portion of the RBCs through its red pulp, which contains 
capillary-like structures composed of macrophages that cull abnormally shaped or 
immunologically recognized RBCs from the filtered erythrocyte population before 
further transit through the red pulp space and reentry through slits in basement 
membranes of a large network of venous sinuses. (Koury, 2014) 
Eryptosis is increased in a wide variety of diseases including sepsis, haemolytic 
uremic syndrome, malaria, sickle cell anemia, beta-thalassemia, glucose-6-
phosphate dehydrogenase deficiency, phosphate depletion, iron deficiency and 
Wilson's disease. Eryptosis can be elicited by osmotic shock, oxidative stress, 
energy depletion as well as a wide variety of endogenous mediators and 
xenobiotics. (Lang and Qadri, 2012) 
 
1.2. RBCs functions 
RBCs cytosol consist mainly of hemoglobin (Hb), a complex metalloprotein 
containing heme groups whose iron atoms temporarily bind to oxygen molecules 
(O2) in the lungs and release them throughout the body. Oxygen can easily diffuse 
through the RBCs plasma membrane. Hb in the RBCs also carries some of the 
waste product carbon dioxide back from the tissues; most waste carbon dioxide, 
however, is transported back to the pulmonary capillaries of the lungs as 
bicarbonate (HCO3
-
) dissolved in the blood plasma.  
The blood plasma alone is straw-colored, but the red blood cells change color 
depending on the state of the Hb: when combined with oxygen the resulting 
oxyhemoglobin is scarlet, and when oxygen has been released the resulting 
deoxyhemoglobin is of a dark red color. Hb also has a very high affinity for 
carbon monoxide, forming carboxyhaemoglobin which is a very bright red in 
color.  
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1.2.1. Oxygen transport 
Hb is an allosteric oxygen-transport protein. In adult humans the Hb molecule 
consists of four subunits, each having one polypeptide chain and one heme group. 
All Hbs carry the same prosthetic heme group iron protoporphyrin IX associated 
with a polypeptide chain of 141 (alpha) and 146 (beta) amino acid residues. The 
ferrous ion of the heme is linked to the N atom of a histidine. The porphyrin ring 
is wedged into its pocket by a phenylalanine of its polypeptide chain. The 
polypeptide chains of adult Hb themselves are of two kinds, known as alpha and 
beta chains, similar in length but differing in amino acid sequence. The alpha 
chain of all human Hb, embryonic and adult, is the same. The non-alpha chains 
include the beta chain of normal adult Hb (α2β2). Oxygen binds reversibly to the 
ferrous iron atom in each heme group. The heme group that has become oxygen 
bound varies with the partial pressure of oxygen. The sigmoid shape of the 
oxygen equilibrium curve shows that there is cooperative interaction between 
oxygen binding sites. Hence, as oxygen action proceeds, combination with further 
molecules of oxygen is made easier. (Marengo-Rowe, 2006) 
Hb function as an oxygen-carrier in the blood is fundamentally linked to the 
equilibrium between the two main states of its quaternary structure. Hb exists in 
two different conformational states, the T state being dominant in the absence of 
the ligand and the R state when the protein is fully saturated. The unliganded 
(deoxy) form is called the "T" (for "tense") state because it contains extra 
stabilizing interactions between the subunits. In the high-affinity R-state 
conformation the interactions which oppose oxygen binding and stabilize the 
tetramer are somewhat weaker or "relaxed". (Bellelli and Brunori, 2011) 
Under the conditions of lower temperature, higher pH, and increased oxygen 
pressure in the capillaries of the lungs, the reaction proceeds to the right. The 
purple-red deoxygenated hemoglobin of the venous blood becomes the bright-red 
oxyhemoglobin of the arterial blood. Under the conditions of higher temperature, 
lower pH, and lower oxygen pressure in the tissues, the reverse reaction is 
promoted and oxyhemoglobin gives up its oxygen. (Bellelli and Brunori, 2011) 
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Although the oxygen transported by RBCs make possible cellular respiration 
throughout the body, RBCs lack mitochondria and so cannot perform cellular 
respiration themselves and must subsist on glycolysis.  
 
1.2.2. Carbon dioxide transport 
Carbon dioxide (CO2) is generated in the tissues, but only about 5% of the CO2 
dissolves directly in the blood plasma. The 95% of the CO2 coming from the 
tissues is carried in the RBCs. It enters and then leaves the cell by diffusion 
through the plasma membrane. Once inside, about one-half of the CO2 is directly 
bound to Hb (at a different site from the one that binds oxygen).  
The rest is converted by the enzyme carbonic anhydrase (CA) in carbonic acid, 
which dissociates into a hydrogen ion (H
+
) and a bicarbonate ion: 
 
CO2 + H2O ↔ H2CO3 ↔ H
+
 + HCO3
−
 
  
Bicarbonate resulting from CA action, is transported into the plasma in exchange 
for extracellular chloride by band 3, the key protein for the blood’s capacity to 
carry CO2. When the RBCs reach the lungs, these reactions are reversed and CO2 
is released to the air of the alveoli. (Geers and Gros, 2000) 
CAs are ubiquitous metalloenzymes participating in a variety of physiological and 
pathological processes that involve pH regulation, CO2 and HCO3
- 
transport, ion 
transport, biosynthetic reactions, bone resorption and tumorigenicity. 
In mammals, 16 isozymes have been identified that differ in catalytic activity, 
subcellular localization and tissue distribution. RBCs typically express both (fast) 
CA II and higher concentrations of (slow) CA I. (Gilmour, 2010) 
The biological functions of CAs are of great interest, as their contribution to the 
development of complications in some pathologies is not yet completely clarified. 
CA II plays an important role in the production of aqueous humour and much 
attention has been focused on the synthesis and characterization of CA II 
inhibitors, particularly in the treatment of glaucoma (Weiwei and Hu, 2009).  
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1.3. RBCs membrane: structure and function 
The membrane of the RBCs plays many roles that aid in regulating their surface 
deformability, flexibility, adhesion to other cells and immune recognition. These 
functions are highly dependent on its composition, which defines its properties. 
The RBCs membrane is composed of 3 layers: the glycocalyx on the exterior, 
which is rich in carbohydrates; the lipid bilayer which contains many 
transmembrane proteins, besides its lipidic main constituents; and the membrane 
skeleton, a structural network of proteins located on the inner surface of the lipid 
bilayer. Half of the membrane mass in human RBCs are lipids and the other half 
are proteins. (Yazdanbakhsh et al., 2000) 
 
1.3.1. Lipide domain 
The main lipids are cholesterol and phospholipids. The RBCs membrane 
comprises a typical lipid bilayer, similar to what can be found in virtually all 
human cells. The lipid composition is important as it defines many physical 
properties such as membrane permeability and fluidity and also the activity of 
many membrane proteins is regulated by interactions with lipids in the bilayer. 
Although cholesterol seems equally distributed between the two halves or leaflets 
of the lipid bilayer, the other lipids are asymmetrically distributed. Glycolipids, 
phosphatidylcholine and sphingomyelin are located in the outer half of the 
bilayer; phosphatidylinositols (PIs), phosphatidylethanolamine (PE) and 
phosphatidylserine (PS) occur in the interior layer facing the cytoplasm. (Smith, 
1987) 
This asymmetric phospholipid distribution among the bilayer is the result of the 
function of several energy-dependent and energy-independent phospholipid 
transport proteins. Proteins called “Flippases” move phospholipids from the outer 
to the inner monolayer, while others called “floppases” do the opposite operation, 
against a concentration gradient in an energy dependent manner. Additionally, 
there are also “scramblase” proteins that move phospholipids in both directions at 
the same time, down their concentration gradients in an energy independent 
manner. (Mohandas and Gallagher, 2008) 
15 
 
The maintenance of an asymmetric phospholipid distribution in the bilayer (such 
as an exclusive localization of PS and PIs in the inner monolayer) is critical for 
the cell integrity and function due to several reasons. Macrophages recognize and 
phagocytose RBCs that expose PS at their outer surface. Thus the confinement of 
PS in the inner monolayer is essential if the cell is to survive its frequent 
encounters with macrophages, especially in the spleen. (Mohandas and Gallagher, 
2008) 
An exposure of PS can potentiate adhesion of RBCs to vascular endothelial cells, 
effectively preventing normal transit through the microvasculature. Thus it is 
important that PS is maintained only in the inner leaflet of the bilayer to ensure 
normal blood flow in microcirculation. Both PS and phosphatidylinositol-4,5-
bisphosphate (PIP2) can regulate membrane mechanical function, due to their 
interactions with proteins such as spectrin and protein 4.1R, modulating the 
linkage of the bilayer to the membrane skeleton. 
Proteins in the lipid domain usually extend from the inside of the erythrocyte to 
the outside. These membrane proteins can be divided structurally into an internal 
hydrophilic portion, a membrane hydrophobic portion, and an external 
hydrophilic portion with attached carbohydrates. (Smith, 1987) 
Integral proteins include several glycophorins, aquaporins and  protein band 3.  
The glycophorins (2% of RBC membrane proteins) are glycosylated in their 
extracellular domain and imparts a negative charge to the cell, reducing 
interaction with other cells/ endothelium.  
The aquaporins are selective pores for water transport and allow RBCs to remain 
in osmotic equilibrium with extracellular fluid.  
The membrane protein band 3 serves simultaneously as an anion exchanger 
(plays a critical role in the CO2 transport system), an anchor for the cytoskeleton, 
Hb and glycolytic enzymes and as a senescence antigen. 
 
1.3.2. Cytoskeleton 
Membrane-associated cytoskeletal protein networks are involved in the control of 
cell shape, attachments to other cells and to the substrate, and in organization of 
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specialized membrane domains. Cytoskeletal proteins interact with integral 
proteins and lipids of the bilayer to maintain membrane integrity. 
The cytoskeleton of RBCs form a filamentous network under the lipid bilayer and 
consists of several proteins such as spectrin, ankyrin, actin, and protein 4.1.  
Spectrin is the most prominent component of the RBCs membrane cytoskeleton. 
It is a fibrous polypeptide constituted by two isoforms, alpha (260 kDa) and beta 
(225 kDa). Both proteins are long, flexible structures that are twisted together to 
form heterodimers (Smith, 1987). Tetramers, and possibly higher order oligomers, 
are formed by a “head-to-head” interaction of heterodimers. Two alpha-beta 
helixes are linked end to end to form a single tetramer, which has binding sites for 
several other proteins, including other spectrin molecules. The spectrin tetramers 
are organized into a meshwork that is fixed to the membrane by the protein 
ankyrin. Actin binds to the “tail” of several heterodimers to generate a series of 
polygons (mostly hexagons), with spectrin tetramers as the sides. (Luna and Hitt, 
1992) 
Ankyrin is itself connected to a transmembrane protein band 3. The purpose of 
band 4.2 (palladin, 72 kDa) may be to stabilize the link between ankyrin and the 
anion exchanger. Spectrin is also linked to a transmembrane protein called 
glycophorin C (25 kDa) by the protein known as band 4.1. Thus the meshwork is 
anchored to the membrane at multiple sites. (Luna and Hitt, 1992) 
Actin subunits (subunit mass of 43 kDa), actually form short microfilaments 
consisting of filamentous actin and tropomyosin (isoforms of 27 and 29 kD). The 
protein tropomodulin is also associated with filamentous actin. Band 4.9 protein, 
known also as dematin (48 kDa) may crosslink some of the actin microfilaments 
to make bundles of f (filamentous) actin. 
Membrane protein Band 4.1 (78 kDa) promotes and stabilizes the association of 
spectrin with actin as does the protein adducin. (Luna and Hitt, 1992) 
 
1.4. Protein Band 3 
Band 3 is a multifunctional transmembrane protein, which is the most abundant 
protein in the RBCs plasma membrane (1.2×l0
6 
copies per cell, about of 25% of 
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the total membrane protein) (Low, 1986). The protein band 3 is an anion 
exchanger (Anion Exchanger 1- AE1, SLC4A1), expressed in erythroid cells and 
the kidney, but also serves as a protein anchor, connecting soluble cytoplasmic 
proteins and components of the cytoskeleton to the membrane, hemoglobin, and 
glycolitic enzymes, as well as a senescence antigen (Tanner, 2002) 
This integral protein (911 amino acid; 95 kDa) has three distinct functional 
domains: the large N-terminal domain and short C-terminal tail of the protein are 
both located in the cytoplasm and the transmembrane domain (Fig. 2). 
 
 
Figure 2. Structural domains of RBCs protein band 3. 
 
The N-terminal domain (Cdb3) (residue l-360; molecular weight of 43 kDa) not 
only anchors the RBCs skeleton by association with ankyrin and protein 4.1 but 
also binds an array of other proteins, including protein 4.2, the glycolytic enzymes 
glyceraldehyde 3-phosphate dehydrogenase, aldolase and phosphofructokinase the 
tyrosine kinase p72syk and deoxyhemoglobin.  
The C-terminal domain (amino acids 361–911; 52 kDa) comprises 12–14 
transmembrane (TM) segments with a short (33 amino acid) cytoplasmic tail. The 
C-terminal tail harbors a binding site for carbonic anhydrase II (CA II), essential 
for the erythrocyte-based system that moves carbon dioxide from the tissues to the 
lungs. The central integral membrane domain performs chloride-bicarbonate 
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exchange, also contains a single N-linked glycosylation site on its extracellular 
surface that is not required for transport. (Van den Akker et al., 2010) 
 
The main functions of band 3 may be summed up into: anion exchanger, anchor 
of proteins and marker of senescence. 
Band 3 multi-spanning integral membrane domain has an anion exchanger 
function and plays a critical role in the CO2 transport system. Since the solubility 
of carbon dioxide in the blood is rather low, the CO2 molecule which diffuses into 
the RBCs through the plasma membrane is converted into HCO3
-
 by cytosolic 
carbonic anhydrase. The bicarbonate anion is then transported out of the cell by 
the band 3 protein in exchange for a Cl
-
 anion. When the blood reaches the lung, 
the above exchange process is reversed as a result of a CO2 pressure gradient 
between the blood and the lung alveoli. One site of band 3 expression is in the 
kidney where its anion exchange activity may have a role in pH regulation of 
blood. (Jennings, 1985; Wang, 1994; Jay, 1996) 
 
 
Figure 3. The interactions of band 3 in cell shape, anion exchange, 
and pH regulation. (Jay, 1996) 
 
Band 3, also serves as a protein anchor, connecting soluble cytoplasmic proteins 
and components of the cytoskeleton to the membrane. Spectrin binds to band 3 via 
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ankyrin and band 4.1 (Fig. 3). These interactions with cytoskeletal proteins make 
band 3 essential for maintaining cell shape and mechanical strength. 
It is also known that this protein guarantees glycolysis regulation through 
protein/enzymes binding to its cytoplasmic tail (Ferru et al., 2011) and provides 
binding sites for Hb, hemichrome (Fig. 4). (Wang, 1994; Pantaleo et al., 2008) 
  
 
Figure 4. (Pantaleo et al., 2008) 
 
Band 3 also has a third function. The external RBCs surface is non-immunogenic 
and non-adhesive, to avoid adhesion to endothelia and phagocytosis by spleen, 
liver and bone marrow macrophages, ready to eliminate any cell showing even 
subtle membrane alterations. Internally, the continuous formation of oxidant 
species during the oxygenation-deoxygenation cycles of Hb are opposed by 
powerful detoxication and protection mechanisms of RBCs. What determines the 
RBCs demise is not its fragmentation but its rapid transformation into a non-self 
cell, recognized as such by the phagocytic system and removed. This 
transformation is likely due to rather subtle modifications of the RBCs membrane 
and expression of neo-antigenic sites that lead to opsonization or direct 
recognition by phagocytes. The protein band 3 acts as a senescence antigen for 
aged and damaged red cells. Clustering of band 3 in the RBCs membrane triggers 
binding of antibodies to an extracellular part of the protein (Fig. 4) and causes the 
removal of aged or damaged red cells. (Pantaleo et al., 2008; Arese et al., 2005) 
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1.4.1. Band 3 and membrane proteins interaction 
The membrane integral proteins establish linkages with cytoskeletal proteins and 
may play an important role in regulating cohesion between the lipid bilayer and 
cytoskeleton, likely enabling the RBCs to maintain its favorable membrane 
surface area by preventing the membrane from collapsing (vesiculating). 
 
 
 
Figure 5: Schematic representation of two types of multiprotein complexes in the 
red cell membrane. (Salomao et al., 2008) 
 
Protein complex (Left side of Fig. 5) attached to spectrin near the center of the 
tetramer (dimer–dimer interaction site). Tetrameric band 3 is bound to ankyrin, 
which is bound to spectrin. The membrane skeletal protein 4.2 has binding sites 
for band 3 and for ankyrin. Transmembrane glycoproteins GPA, Rh, and RhAG 
bind to band 3, and CD47 and LW associate with Rh/RhAG. The two cytoplasmic 
domains of band 3 contain binding sites for soluble proteins, the short C-terminal 
domain for cytosolic carbonic anhydrase II (CA II), the large N-terminal domain 
for deoxyhemoglobin and for glycolytic enzymes, aldolase, phosphofructokinase 
(PFK), and glyceraldehyde 3′-phosphate dehydrogenase (GAPDH).  
The right side of the Fig. 5 shows protein complex at membrane cytoskeletal 
junctions. The junctions contain the ternary complex of spectrin, F-actin, and 
4.1R, as well as the actin-binding proteins tropomyosin, tropomodulin, adducin, 
and dematin. 4.1R enters into an additional ternary interaction with the 
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transmembrane protein GPC and p55 and is taken also to bind to band 3, in the 
form of a dimer, which also carries GPA. (Salomao et al., 2008).  
 
1.4.2. Band 3 tyrosine-phosphorylation 
Phosphorylation/dephosphorylation of protein tyrosine residues (Tyr) has been 
implicated in the regulation of several RBCs functions, including metabolic 
pathways (Harrison et al., 1991; Low et al., 1993; De Neef et al., 1996) membrane 
transport (De Franceschi et al., 1997; Musch et al., 1999) and cellular volume and 
shape (Musch et al., 1999; Bordin et al., 1995; Minetti et al., 1998). 
Protein tyrosine kinases (PTKs) identified to date in RBCs include insulin 
receptor tyrosine kinase (Herzberg et al., 1980) and the Syk (Harrison et al., 1994; 
Brunati et al., 1996) and Src-like non-receptor tyrosine kinases (Brunati et al., 
1996; De Franceschi et al., 1997). Among the Src-like tyrosine kinases detected in 
human RBCs, Lyn and Fgr are expressed predominantly, with Hck being found at 
a lower levels (De Franceschi et al., 1997). The attempt at purifying the native 
protein tyrosine kinases from RBCs led to the isolation of substantial amounts of 
only the 2 tyrosine kinases, Syk and Lyn. (Brunati et al., 1996)  
The PTKs belonging to the Src family share a high degree of structural similarity, 
with a common domain architecture and regulatory mechanisms. The Src 
sequence consists of a poorly conserved N-terminal segment, 2 conserved 
domains termed Src homology 3 (SH3) and SH2, followed by the catalytic 
domain, SH1 (Brown and Cooper, 1996). The SH3 and SH2 domains interact with 
protein sequences containing polyproline II helices and phospho-Tyr residues, 
respectively, and play a dual role in Src regulation, because they are both required 
for keeping Src kinase in an inactive state and targeting the enzyme to specific 
substrates (Xu et al., 1997). 
The activity of Src-related kinases is modulated by phosphorylation of 2 tyrosine  
residues: autophosphorylation of Tyr 416 (c-Src numbering), located inside the 
catalytic domain, correlates with enzyme activation,14,18-20 while Csk-mediated 
phosphorylation of the C-terminal Tyr 527 gives rise to inactive forms of Src 
kinases. Indeed, phosphorylated Tyr 527 interacts with the SH2 domain of the Src 
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molecule, thus triggering a reorganization of the enzyme structure that forces the 
kinase to adopt a locked and down-regulated conformation (Xu et al., 1997). 
Syk (p72syk) which is comprised of two tandemly arranged SH2 domains, a 
linker region that is postulated to bind cellular effectors, a catalytic domain that 
includes autophosphorylation sites, and a short carboxyl-terminal extension.  
SHP-2 is a non-transmembrane protein tyrosine phosphatases (PTPs) involved 
in the signaling pathway of a variety of growth factors and cytokines and plays an 
important role in relaying signals from the cell surface to the nucleus. It is 
expressed in human RBCs, where it is mostly present in the cytosol. SHP-2 
containing 2 SH2 domains and interacts with many proteins by recognizing 
specific Tyr-phosphorylated motifs through its amino-terminal SH2 domain 
(Donella-Deana et al., 1998). This protein–protein interaction enhances SHP-2 
activity by relieving the inhibitory intramolecular interactions between the amino-
terminal SH2 domain and the catalytic phosphatase domain. Thus, the SH2 
domains play a crucial role both in the recruitment of cellular substrates and in the 
modulation of the enzyme catalytic activity (Brunati et al., 2000).  
The Tyr-phosphorylated state of cellular proteins reflects the balance between the 
competing activities of PTKs and PTPs. Because the activity of PTPs is much 
higher than that of PTKs, basal levels of protein Tyr-phosphorylation (Tyr-P) in 
cells are very low (Brautigan, 1992; Walton and Dixon, 1993).  
Treatment of human RBCs with pervanadate, diamide, or N-ethylmaleimide 
(NEM), which act as both oxidizing agents and PTPs inhibitors, induces an 
increase in protein Tyr-P. Under these conditions, the multifunctional 
transmembrane band 3 has been demonstrated to represent the main Tyr-
phosphorylated protein (Harrison et al., 1994; Brunati et al., 2000). 
Band 3 has four Tyr-phosphorylatable sites (Fig. 6): Tyr 8, located in the highly 
acidic cytoplasmic domain, has been identified as the major Tyr-P site in vitro; 
Tyr 21, Tyr 359 and Tyr 904 have also been reported to be phosphorylated in 
vitro. (Yannoukakos et al., 1991). 
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Figure 6. Schematic representation of band 3 Tyr-phosphorylatable sites. 
 
Two well characterized protein kinases, Syk (p72syk) and Lyn (p53/56lyn), are 
thought to be responsible for the vast majority of band 3 tyrosine phosphorylation 
(Harrison et al., 1994). Protein tyrosine kinase Syk catalyzes the so-called 
“primary phosphorylation” of band 3 at Tyr 8 and 21 within the cytoplasmic 
domain of the polypeptide (Fig. 7). (Bordin et al., 2005a) 
 
 
Figure 7. Sequential steps underlying the mechanism of phosphorylation and 
dephosphorylation of protein tyrosine residues (Tyr) of band 3 in treated human 
RBCs. 
 
Subsequently, Lyn, recruited to band 3 through an interaction between its SH2 
domain and one of the above mentioned phospho-Tyr, catalyzes the “secondary 
phosphorylation” of band 3 at Tyr 359 and 904 (Brunati et al., 2000). The 
localization of Lyn next to its phosphorylation sites can be easily explained by its 
binding to phosphorylated tyrosines 8 and 21 of band 3, which are positioned in 
the crystal structure adjacent to both Tyr359 and the membrane-spanning domain 
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of band 3.SHP-2, located in the RBCs cytosol, is recruited to the membrane when 
there is increased of band 3 Tyr-P. Band 3 is both anchoring protein and substrate 
for the SHP-2 (Bordin et al., 2002). Upon binding of the N-terminal SH2 domain 
to a specific P-Y359 target, the enzyme adopts an “open” active conformation and 
catalyzes band 3 dephosphorylation on residues Tyr 8, Tyr 21, and Tyr 904 
(Bordin et al., 2002). 
 
1.5. RBCs and oxidative stress 
Reactive oxygen species (ROS) are chemically reactive molecules containing 
oxygen. ROS form as a natural product of the normal metabolism of oxygen and 
have important roles in cell signalling and homeostasis. Effects of ROS on cell 
metabolism include roles in apoptosis, positive effects such as the induction of 
host defence genes and mobilisation of ion transport systems.  
Normally, cells defend themselves against ROS damage with enzymes such as 
superoxide dismutases, catalases, lactoperoxidases, glutathione peroxidases and 
peroxiredoxins. Small molecule antioxidants such as ascorbic acid (vitamin C), 
tocopherol (vitamin E), uric acid and glutathione also play important roles as 
cellular antioxidants. In similar manner, polyphenol antioxidants assist in 
preventing ROS damage by scavenging free radicals.  
Oxidative stress (OS) reflects an imbalance between the generation of ROS and a 
biological system's ability to readily detoxify the reactive intermediates or to 
repair the resulting damage. Chemically, OS is associated with increased 
production of oxidizing species or a significant decrease in the effectiveness of 
antioxidant defences. In general, harmful effects of ROS on the cell are most 
often: damage of DNA, lipid peroxidation, oxidations of amino acids in proteins, 
inactivation of specific enzymes by oxidation of co-factors and disruptions in 
normal mechanisms of cellular signalling. 
RBCs are cells circulating in direct contact with plasma containing steroids, 
proteins or inflammation-related products, such as ROS. 
Many proteins are susceptible to attack by ROS, especially on sulfhydryl groups 
which are among the most easily oxidized protein residues. Oxidation can lead to 
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inter- and/or intra-molecular cross linking thus inducing protein degradation 
(Stadtman and Levine, 2000;  Pacifici and Davies, 1990), clustering (Bordin et al., 
2010a) and enzyme inactivation (Bordin et al., 2010a; Bordin et al., 2005b). 
S-Glutathionylation is the post-translational modification of protein cysteine 
residues by the addition of glutathione, the most abundant and important low-
molecular-mass thiol within most cell types. This post-translational process occurs 
through the reversible addition of a proximal donor of glutathione to thiolate 
anions of cysteines in target proteins, where the modification alters molecular 
mass, charge, and structure/function and/or prevents degradation from sulfhydryl 
overoxidation or proteolysis. For translational application, S-glutathionylated 
proteins may be useful as biomarkers in individuals exposed to agents that cause 
oxidative or nitrosative stress. (Grek et al., 2013) 
 
When treated with diamide, a mild oxidant which induces cysteine disulfide bond 
formation and inhibits tyrosine (Tyr)-protein phosphatase activities (Bordin et al., 
2005a; Bordin et al., 2006), RBCs show a well-defined Tyr-P level of membrane 
proteins, particularly of band 3 (Bordin et al., 2006). This protein has long been 
involved in the senescent process of human RBCs (Lutz et al., 1988; Bosman et 
al., 2005), through mechanisms of either proteolytic fragmentation (Bosman et al., 
2010) or clustering (Bordin et al., 2010a; Bosman et al., 2005), both triggering 
IgG recognition and binding (Bordin et al., 2010a; Lutz et al., 1988). This, in turn, 
allows further recognition and phagocytosis by macrophages which eliminate 
senescent/altered RBCs. (Lutz et al., 1988; Bosman et al., 2005; Bosman et al., 
2010; Bratosin et al., 1998) 
Alterations in diamide-induced band 3 Tyr-P levels represent pre-existing 
membrane status modifications, like those observed in glucose-6-phosphate 
dehydrogenase (G6PD)-deficient patients (Bordin et al., 2010a; Bordin et al., 
2005b), suffering chronic impairment of antioxidant defenses, or in patients with 
endometriosis (Bordin et al., 2010b) or polycystic ovary syndrome (PCOs) (Donà 
et al., 2012), with systemic inflammation. Diamide triggers band 3 Tyr-P (Bordin 
et al., 2005a; Bordin et al., 2005b; Bordin et al., 2006) and aggregation in high 
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molecular weight aggregates (HMWA), both useful parameters in the evaluation 
of oxidation-related damage to cells (Bordin et al., 2010a; Bordin et al., 2006).  
 
 
2. ALDOSTERONE 
Aldosterone (Aldo) is a steroid hormone (mineralocorticoid family) produced by 
the outer section of the cortex (zona glomerulosa) in the adrenal gland.  
As the name of this class of hormones implies, the mineralocorticoids control the 
excretion of electrolytes.  
 
 
Figure 8. Molecular structure of aldosterone. 
 
 
Aldo plays a central role in the regulation of blood pressure mainly by acting on 
the distal tubules and collecting ducts of the nephron, increasing reabsorption of 
sodium and water in the kidney, potassium secretion and sustains a constant extra 
cellular fluid volume (Funder, 2010). However, the action of Aldo is exerted on 
sweat glands, stomach, and salivary glands to the same effect, i.e. sodium 
reabsorption. This action is accompanied by the retention of chloride and water 
resulting in the expansion of extracellular volume.  
 
2.1. Aldosterone synthesis and regulation 
The corticosteroids are synthesized from cholesterol within the zona glomerulosa 
of adrenal cortex. Many of the enzymes of adrenal steroid hormone synthesis are 
of the class called cytochrome P450 (CYP).  
Aldosterone and corticosterone share the first part of their biosynthetic pathways.  
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Figure 9. Aldosterone biosynthesis from cholesterol. 
 
In order for cholesterol to be converted to pregnenolone in the adrenal cortex it 
must be transported into the mitochondria where CYP11A1 resides. This transport 
process is mediated by steroidogenic acute regulatory protein (StAR) and it is the 
rate-limiting step in steroidogenesis. 
Conversion of pregnenolone to progesterone requires the enzyme 3β-
hydroxysteroid-dehydrogenase type 1 (gene symbol HSD3B2) and the enzyme 
11β-hydroxylase (CYP11B1) transforms 11-deoxycorticosterone in 
corticosterone. 
Zona glomerulosa cells are unique in the adrenal cortex in containing the enzyme 
responsible for converting corticosterone to aldosterone, the principal and most 
potent mineralocorticoid. This enzyme is CYP11B2, also called aldosterone 
synthase. (Connell and Davies, 2005) 
 
2.1.1. The role of the renin-angiotensin system 
Renin is synthesized and released by the juxtaglomerular cells in the afferent 
arteriole of the kidney in response to a decrease in intravascular volume detected 
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by baroreceptors. Pressure-sensitive baroreceptors are found in the vessel walls of 
nearly all large arteries in the thorax and neck, in particular in carotid arteries and 
in the aorta. These specialized receptors are sensitive to changes in mean arterial 
pressure and detect low blood pressure or low blood volume. In response to 
hypotension, renin is released by the kidney and cleaves angiotensinogen into 
angiotensin I, which is converted to angiotensin II by angiotensin converting 
enzyme (ACE). Angiotensin II acts on vascular smooth muscle to cause 
vasoconstriction, and on the adrenal zona glomerulosa to stimulate aldosterone 
production. The adrenal response to Ang II occurs within minutes, a time course 
that implies that no new protein synthesis is required (Connell and Davies, 2005). 
Angiotensin II and a variety of secondary factors (potassium and sodium 
concentrations, adrenocorticotropic hormone (ACTH) and vasopressin) induce 
Aldo synthesis in adrenal zona glomerulosa cells. Aldo is released to the 
circulation, promotes sodium retention in the kidney, and exerts direct effects in 
the heart and other organs (Spat and Hunyady, 2004).  
 
2.1.2. Other regulator factors 
Aldo has an essential role in maintaining extracellular fluid and thereby 
circulation and  its secretion is controlled by several factors. Most or all increases 
in Aldo secretion may be attributable to increased activity of the renin-angiotensin 
system and/or increased plasma level of K
+
. 
Under physiological conditions the control of secretion is probably confined to the 
stimulatory factors ACTH, angiotensin II (ANG II), and K+ concentration.  
Aldo secretion is also increased during acute or chronic sodium depletion, fluid or 
blood loss, erect postural position, dietary potassium loading, tissue damage 
leading to hyperkalemia and pregnancy. 
When sodium or fluid loss is severe, ACTH is also secreted and synergizes with 
ANG II or K
+
 in stimulating glomerulosa cells. Inhibitory factor atrial natriuretic 
hormone (ANP) secretion is increased in response to sodium and/or water loading, 
and it in turn inhibits aldosterone secretion. (Hattangady et al., 2012) 
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The aldosterone production is also affected to one extent or another by nervous 
control, which integrates the inverse of carotid artery pressure, pain, posture and 
probably emotion.  
 
2.2. Aldosterone functions  
The steroid hormone Aldo controls sodium and potassium balance and also 
influences acid-base homeostasis of the vertebrate organism. 
Its major physiological targets are the epithelial cells, of which the most important 
are located in the distal nephron. Aldo augments Na
+
 reabsorption as well as K
+
 
and H
+
 excretion, acting on the nuclear mineralocorticoid receptors (MR) within 
the cells of the distal tubule and the collecting duct of the kidney nephron. In these 
cells Aldo upregulates and activates the basolateral Na
+
/K
+
 pumps and this in turn 
results in reabsorption of sodium (Na+) ions and water (which follows sodium) 
into the blood and secretion of potassium (K+) ions into the urine (Briet and 
Schiffrin, 2011). 
Aldo upregulates also epithelial sodium channels (ENaCs), increasing apical 
membrane permeability for Na
+
. Cl
−
 is reabsorbed in conjunction with sodium 
cations to maintain the system's electrochemical balance. Through changes in 
sodium balance, Aldo influences the extracellular fluids and blood pressure.  
In addition to its epithelial actions, Aldo influences the function of various non-
epithelial tissues, particularly the cardiovascular system and central nervous 
system (CNS). In contrast to its established effects on electrolyte balance in 
epithelial tissue, Aldo in the cardiovascular system promotes cardiac hypertrophy, 
fibrosis and abnormal vascular endothelial function. In the CNS, it appears to 
regulate blood pressure, salt appetite and sympathetic tone. (Connell and Davies, 
2005). 
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2.3. Genomic and non-genomic pathway 
Aldo exerts its function by binding to classical mineralocorticoid receptor (MR) 
acting as ligand-dependent transcription factor (Robert-Nicoud et al., 2001; Yang 
and Fuller, 2012). Over the last decade, there has been an increasing amount of 
evidence showing the dual effect of Aldo. In the first pathway, termed “genomic”, 
Aldo binds to the MR which, being linked to several other proteins in a cytosolic 
complex, dissociates and translocates to the nucleus to regulate target gene 
expression (Yang et al., 2011).  
The MR is expressed in renal epithelial cells and also in non-epithelial tissue such 
as the heart and the brain. Aldosterone exerts its effects on water homeostasis by 
transcriptional regulation of serum-glucocorticoid regulated kinase 1 (Sgk1), 
epithelial sodium channels (ENaC), sodium-potassium-ATPase, and other entities 
in renal collecting duct cells. (Lother et al., 2014) 
In the second pathway, Aldo elicits rapid “non-genomic” effects on second 
messenger systems and signaling cascades of different tissues (Boldyreff and 
Wehling, 2003; Dooley et al., 2012). Aldo mediates rapid effects such as the 
activation of protein kinase C (PKC), protein kinase D (PKD), extracellular 
signal-regulated kinase (ERK1/2) and mitogen-activated protein kinase (MAPK) 
cascades through the transactivation of the epidermal growth factor receptor 
(EGFR), via the non-receptor tyrosine kinase, c-Src. Signalling cascades coupled 
to EGFR transactivation either directly modulate membrane targets through their 
phosphorylation or alternatively modulate the expression of membrane targets 
through the phosphorylation of transcription factors such as CREB or MR. 
(Dooley et al., 2012) 
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Figure 10. Genomic and nongenomic actions of aldosterone and interaction with the 
mineralocorticoid receptor. (Lastra et al., 2010) 
 
Inappropriately high plasma level of Aldo contribute to progressive organ damage 
to the heart (Reil et al., 2012; Funder, 2010; Funder, 2011), vasculature (Rocha et 
al., 1998) and kidney (Shibata and Fujita, 2012; Egido, 1996; Berl et al., 1978), 
promoting myocardial (Swynghedauw, 1999; Qin et al., 2003; Nakamura et al., 
2009) and vascular fibrosis (Tylicki et al., 2008), oxidative stress (Patni et al., 
2007; Pu et al., 2003) and perivascular inflammation (Pu et al., 2003). 
 
 
2.4. Aldosterone and oxidative stress 
The hypothesis of Aldo induced oxidative stress was confirmed in patients with 
chronic heart failure since they showed increased amounts of plasma markers of 
oxidative stress, e.g. oxidized low-density lipoprotein and 8-isoprostane (Kotlyar 
et al., 2006; Yamaji et al., 2009). Macrophages isolated from these patients, after 
treatment with the MR blocker spironolactone, exhibited lower levels of 
superoxide release and lipid peroxides than macrophages taken before the 
spironolactone treatment (Keidar et al., 2005), revealing an important systemic 
source of MR-induced oxidative stress. Also, in patients with essential 
hypertension, who often present criteria of hyperaldosteronism, plasma markers of 
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oxidative stress (OS) like isoprostanes were elevated (Laffer et al., 2006; Stehr et 
al., 2010). 
A first investigation of Aldo-mediated effects on human cells was conducted on 
cells isolated from an adrenal adenoma in comparison to cells from normal 
adrenal tissue. In the adenoma cells, which had been exposed to high 
concentrations of the locally produced Aldo, the expressions of anti-oxidative 
proteins as well as the expression of the superoxide generating enzyme NADPH 
oxidase were increased (Calò et al., 2010). 
 
 
3. MINERALOCORTICOID RECEPTOR  
The mineralocorticoid receptor (MR) derived from the NR3C2 gene, belongs to 
the steroid/thyroid hormone receptor super-family including glucocorticoid (GR), 
thyroid (THRA, THRB), retinoic acid (RAR), vitamin D (VDR) and other orphan 
receptors. In humans, the NR3C2 gene located in the locus 4q31.1, encodes for a 
984 amino acids (aa) protein that makes MR the largest steroid receptor (Faresse, 
2014). As all the nuclear receptors, the MR protein structure is divided in three 
domains; a N-terminal domain (NTD) of 602 aa involved in the control of the 
transcriptional activity of the receptor; the central DNA-binding domain (DBD) of 
66 aa involved in the binding of the specific response element found on the 
promoter of MR target genes; and finally a ligand-binding domain (LBD) of 251 
aa responsible for the selectivity of hormone binding (Faresse, 2014). The high 
homology of MR LBD with GR LBD, allows MR to bind two types of hormones: 
the mineralocorticoids, represented principally by aldosterone, and the 
glucocorticoids represented by and cortisol in humans (Baker et al., 2013). 
Upon hormonal activation, MR is translocated into the nucleus, where it binds to 
transcriptional co-factors to regulate the expression of target genes. The nuclear 
translocation of MR can be achieved either as a homodimer, or associated to GR 
as a heterodimer. 
The ligand-dependent transcription, also called the late response (after 30 min to 
1h), is well characterized and induces the regulation of hundreds of target genes. 
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These genes present a palindromic DNA sequence common for GR and MR 
called glucocorticoid response element within their promoter (Fuller et al., 2000). 
A unique response element specific for MR has not been yet identified. In 
addition to the late response, an early response has been also described. This early 
phase occurs within minutes after ligand treatment and activates a variety of 
second messengers (Grossmann and Gekle, 2009). 
The MR-positive tissues can be divided in two groups: the epithelial and non-
epithelial tissues. Given the high concentration of circulating glucocorticoids 
(100–1000 fold higher than Aldo) it was proposed that glucocorticoids are the 
principal ligand of MR in these tissues (Connell and Davies, 2005). 
However, in epithelial tissues, such as nephron, colon, trachea or salivary glands, 
MR expression is always associated with the 11-β-hydroxysteroid dehydrogenase 
2 (11-β-HSD2) that allows the selectivity of MR binding to Aldo by converting 
the glucocorticoids to their inactive forms (Albiston et al., 1994; Baker et al., 
2013).  
The regulation of MR signaling can occur at different levels: the amount of 
hormone available locally, the interacting proteins in the cytoplasm and in the 
nucleus as transcriptional co-factors, the regulation of the nucleo-cytoplasmic 
shuttling, the cross-talk with other signaling pathways and finally the post-
translational modifications (PTMs) of the receptor. Numerous modifications have 
been characterized including phosphorylation, glycosylation, ubiquitylation, 
neddylation, nitrosylation, methylation, acetylation, sumoylation and lipidation. 
These PTMs are able to regulate all aspects of normal cell biology and 
pathogenesis (Faresse 2014). 
 
 
4. PRIMARY ALDOSTERONISM 
Primary Aldosteronism (PA) is the most common form of endocrine hypertension 
characterized by excessive Aldo secretion by the adrenal glands, relatively 
autonomous of the renin-angiotensin system (RAS).  
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This overproduction of Aldo is not a consequence of excessive renin stimulation 
but results from autonomous secretion from the adrenal cortex. It is caused in the 
majority of cases by a unilateral aldosterone producing adenoma or bilateral 
adrenal hyperplasia and is often accompanied by hypokalemia (Zennaro et al., 
2014).  
Only a minority of the PA cases are familial and due to known 
(CYP11B2/CYP11B1 chimeric gene or mutations in the KCNJ5 gene) or 
unknown causes (Lenzini and Rossi, 2014). 
Although Aldo excess is directly linked to the development of hypertension 
through renal sodium and water retention it also induces tissue inflammation with 
subsequent fibrosis and remodeling in organs such as the kidney (Shibata and 
Fujita, 2012; Egidio, 1996), heart and vasculature (Reil et al., 2012; Funder, 2010; 
Rocha et al., 1998). As a consequence, PA leads to the development of renal 
impairment, atrial fibrillation (Reil et al., 2012), stroke and myocardial infarction 
(Funder, 2010; Rocha et al., 1998). 
However, due to the absence of PA related specific symptoms and signs there is 
substantial delay in establishing the diagnosis that may affect the response to 
treatment and overall prognosis. Thus, early diagnosis is of paramount importance 
in order to initiate specific treatment by either surgical removal of the 
hyperfunctioning adrenal lesion(s) or administration of targeted medical treatment 
with mineralocorticoid receptor antagonists (Zennaro et al., 2014).  
 
 
35 
 
AIM OF THE STUDY 
 
In previous studies (Bordin et al., 2005b; Donà et al., 2012; Bordin et al., 2010b; 
Andrisani et al., 2014), we identified in the Tyr-P process of RBC membrane band 
3 an important parameter able to discriminate between normal volunteers and 
patients with inflammatory diseases, such as glucose 6 phosphate dehydrogenase 
deficiency (G6PDd), polycystic ovary syndrome (PCOs) and endometriosis. In all 
these pathologies the common feature was an impairment of the GSH-related 
antioxidant activities, situation leading to RBCs membrane alterations. In un-
treated conditions, no difference between healthy controls and patients may be 
seen, but, in the presence of diamide, blind oxidant, enhanced Tyr-P levels in 
patients are clearly found. More interestingly, the increases of Tyr-P in 
membranes are directly proportional to the extent of the oxidizing-related 
parameters, such as lowering of the cytosolic glutathione following diamide 
treatment and increase in glutathionylated membrane proteins. 
Aldosterone (Aldo), besides regulating fluid and electrolyte homeostasis by 
stimulating gene expression of proteins involved in Na+ and K+ regulation and 
reabsorption in renal tissues, can also induce oxidative stress (Patni et al., 2007) 
and perivascular inflammation (Pu et al., 2003) by directly activating or inducing 
gene expression of NADPH oxidase system. For this reason, patients with high 
plasma Aldo content as in Primary Aldosteronism (PA) could have similar if not 
identical alterations as those evidenced in the inflammatory diseases described 
above.  
The aim of this study was, at first, to ascertain if in PA RBCs were effectively 
altered as in other inflammatory diseases, and, then, to investigate how Aldo 
effects could induce eventual membrane alterations since a genomic way was to 
be ruled out in these cells and direct effect on enzymes such as protein kinases, 
phosphatases and structural protein have not yet been established in these cells. 
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MATERIALS AND METHODS 
 
1. MATERIALS 
Anti-phospho-tyrosine (P-Tyr) (PY20) mouse monoclonal antibody was obtained 
from Biosource-Invitrogen (Camarillo, CA, USA). The protease inhibitor cocktail 
and anti-actin mouse monoclonal antibody came from Calbiochem (Darmstadt, 
Germany). Anti-mouse, anti-rabbit and anti-sheep secondary antibodies 
conjugated with horseradish peroxidase (HRP) were obtained from Merck 
Millipore (Darmstadt, Germany). 
Anti-Carbonic Anhydrase (CA) 2 cross reacting also with CA1 sheep polyclonal 
antibody was obtained from Abcam (Cambridge, United Kingdom). Anti-GSH 
was obtained from Virogen (Watertown, MA USA). 
Antibodies anti-SHP2, anti-HSP90 and anti-GAPDH were purchased from Santa-
Cruz Biotechnology, Inc. (CA, USA); anti-Syk and anti-phospho-Src (Tyr416) 
came from Millipore (Temecula, CA, USA). 
Antibody anti-MR (MCR H-300), raised against aminoacids 1-300 of the C-
terminal region of MR was purchased from Santa-Cruz Biotechnology, Inc.; anti-
MR (MA 1-620), produced with aldosterone-3 as immunogen, came from Thermo 
Scientific (Rockford, IL, USA); protein prestained standards from Bio-Rad 
(Milan, Italy). Anti-band 3 antibody, molecular weight markers and any other 
reagents were purchased from Sigma (Milan, Italy).  
 
 
2. STUDY PROTOCOL 
Twenty-two untreated patients affected by PA by serum Aldo levels (intra- and 
inter-assay variations 5.3% and 7.0 %), aldosterone/renin ratio (ARR) and plasma 
renin activity (PRA) and 12 (6 males and 6 females) healthy volunteers as control 
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(HC) were enrolled at the Department of Medicine - Endocrinology of the 
University of Padova, Italy. 
Diagnosis of PA was defined by the presence of aldosterone-renin ratio (ARR) > 
30 (ng/dL)/(ng/mL/h), the lack of aldosterone suppression (<5 ng/dL) following 
an intravenous saline load (2 L of 0.9% saline infused over 4 hours) and the 
persistence of ARR > 30 (ng/dL)/(ng/mL/h) 90 minutes after the administration of 
50 mg of captopril orally. Every patient underwent also an adrenal computed 
tomography (CT) scan and an adrenal venous sampling for subtype classification 
of PA. Before the study, all patients had stopped anti-hypertensive drugs 
interfering with the renin-angiotensin-aldosterone system for 4 weeks. The anti-
hypertensive therapy was switched to an alpha-blocker (doxazosin) and/or 
calcium channel blocker (amlodipine). Patients with hypokalemia have continued 
with oral potassium supplementation. All the subjects were following an 
unrestricted normocaloric diet and undertook a normal physical activity; their 
sodium intake was not restricted and it was calculated at about 150 mmol/day. 
None of the patients were affected by chronic inflammatory disease. 
 
      
Parameter 
Normal 
range 
PA Patients 
(n=22) 
Age (yr) - 55.4±11.3 
BMI (kg/m²) - 27.5±3.4 
Blood pressure 
(mmHg)   
     Systolic <120 155.3 ± 14.1 
     Diastolic <80 97.5± 13.2 
Sodium (mEq/L) 135-145 141.9±1.9 
Potassium (mEq/L) 3.5-4.5 3.3±0.5 
Aldosterone (ng/dL) 3.5-30 44.1±12 
PRA (ug/L/h) 1.3-5.2 0.7±0.3 
ARR < 30 123.4±66.5 
 
Table 1. Baseline clinical characteristics and haematochemical parameters of PA 
patients. Data are means ±SD. 
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At study entry, blood samples were collected from each subject to measure 
sodium, potassium, serum Aldo and PRA in upright position. Citrated blood 
samples were also collected for experimental procedures. During the same visit, 
anthropometric (weight, height and body mass index (BMI)) and clinical (heart 
rate, systolic and diastolic blood pressure) measurements were taken for all 
subjects. Clinical characteristics and biochemical parameters determined in the 
group of PA patients are listed in the Table 1.The Ethics Committee for Research 
and Clinical Trials of our University was notified and all participants gave their 
informed written consent prior to sample collection, according to the Declaration 
of Helsinki. 
 
 
3. METHODS 
3.1. Treatment of RBCs 
Fresh blood, collected from patients and healthy volunteers, was centrifuged at 
3750×g for 3 min.  
 
After removal of supernatant, packed RBC were washed three times at 3750×g for 
3 min in 5 volumes of Dulbecco’s Phosphate Buffered Saline (D-PBS). Packed 
cells (50 µl) were resuspended (at 20% hematocrit) in D-PBS and treated at 35°C 
for 30 min in absence (Basal) or presence (Diamide) of 1.5 mM diamide (dissolved in 
D-PBS) (Bordin et al., 2005b; Bordin et al., 2010b; Donà et al., 2012).  
When the effect of Aldo was evaluated in vitro, only blood from HCs (n=12) was 
centrifuged at 3750×g for 3 min and plasma, not contaminated by leukocytes, was 
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further centrifuged at 1000×g for 20 min to obtain platelet-poor plasma (PPP) 
(Bordin et al., 2013). In order to remove small molecular weight macromolecules 
such as steroid and peptide hormones, dextran-coated charcoal was prepared 
(Bordin et al., 2013) by adding 500 mg of charcoal into the solution containing 50 
mg of dextran and 100 mL D-PBS. The dextran-coated charcoal, or an equal 
volume of the same solution containing only dextran as control, was mixed with 
PPP (1:1). After stirring overnight at 4
o
C, charcoal was removed by centrifugation 
and the Charcoal-stripped (CS-PPP) and unstripped (PPP) were obtained. The 
following day fresh RBC were obtained by the same volunteers who underwent a 
second blood sampling and RBC were purified as described above. RBC were 
washed three times in D-PBS as described above and packed cells were pre-
incubated at 37
o
C for 1 or 24h with PPP or CS-PPP at 20% hematocrit in absence 
(C) or presence of increasing concentrations of aldosterone (Aldo) with or without 
1 µM canrenone (Can) or 5 µM cortisol (Cort) for 1h at 37°C. Stock solutions of 
500 M Aldo and Can were prepared in ethanol and further diluted in D-PBS to 
500 nM and 50 M, respectively, before use.  
At the end of pre-incubation, samples were further incubated in the presence or 
absence of 1.5 mM diamide for 30 min and then recovered by centrifuging at 
800×g for 3 min. 
An aliquot of each sample was successively hemolysed in 30 volumes of 
hypotonic buffer (5 mM sodium phosphate, pH 8, 0.02 % sodium azide, 1 mM 
sodium orthovanadate, and a protease inhibitor cocktail). Membranes were 
separated from the cytosol by centrifugation (16100×g for 20 min in an Eppendorf 
centrifuge) and washed once in hypotonic buffer.  
Both cytosol and membranes were submitted to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting, 
immunostained with the appropriate antibodies and bands were densitometrically 
scanned. 
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3.2. SDS-PAGE  
Aliquots of membranes (10 µg) or cytosol were submitted to SDS-PAGE (8% 
gels). Samples were diluted into suitable quantity of sample buffer (2.5% SDS, 
10% glycerol, 0.004% pyronin) and reduced/denaturated by heating to 100°C for 
5 min with 1 M β-mercaptoethanol before run. When required, β-mercaptoethanol 
was avoided to analyze samples in non-reducing conditions. Separation was 
performed at constant current (50 mA) in running buffer (50 mM Tris-HCl pH 
8.4, 0.38 M glycine, 5mM EDTA, 3.4 mM SDS in H2O). 
 
3.3. Western blotting and immuno-detection 
Gel-separated samples were electro-transferred on nitrocellulose membrane at 350 
mA constant current for 2 h and 30 min into blotting buffer (25 mM Tris-HCl, 192 
mM glycine, 20% v/v methanol and SDS 0.1%, pH 8.0). Immunological detection 
was then performed using appropriate primary antibodies and HRP-conjugated 
anti-rabbit and anti-mouse secondary antibodies. All washes were done with 
washing buffer (Tris-HCl 50 mM, pH 7.5, NaCl 150 mM, Tween 0.1%), 
saturation with Tris-HCl 50 mM, pH 7.5, NaCl 150 mM, bovine serum albumin 
(BSA) 3% and antibodies were diluted with Tris-HCl 50 mM, pH 7.5, NaCl 150 
mM, BSA 1%.  
Detection was done with freshly prepared solution by Amersham and 
densitometric analysis of immunoblots was obtained by the Image Station 4000 
MM PRO (KODAK). 
 
3.4. Determination of parameter variation 
Band 3 variation (VTyr-P ): Band 3 Tyr-P levels were evaluated densitometrically. 
The Tyr-P value of diamide-treated RBC from PA patients or Aldo-treated 
samples (Tyr-Px) was calculated as the ratio to the Tyr-PC, i.e. Tyr-P level of 
diamide-treated RBC obtained in HC or in PPP 0 (0 nM Aldo) or in CS-PPP 0 
(chosen as arbitrary comparison unit, experimentally determined as value±SD), 
according to the following formula: 
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VTyr-P  = (Tyr-PX/Tyr-PC)-1. 
 
HMWA variation (VHMWA): membranes (1 g), were analysed by SDS-PAGE 
(8%) in non-reducing conditions, immunostained with anti-band 3 antibody and 
bands were densitometrically scanned. Amount of band 3 HMWA in control cells 
(HC or in unstimulated conditions) was chosen as arbitrary unit. Results represent 
means  SD of six separate experiments in duplicate. The formula for VHMWA 
calculation was: 
VHMWA = (HMWAX/HMWAC)-1 
 
IgG variation (VIgG): membranes (8 g) from diamide-untreated RBC were 
analysed by SDS-PAGE (8%), immunostained with anti-human IgG antibody and 
bands were densitometrically scanned. Amount of IgG in control cells (IgGC) was 
chosen as arbitrary unit. Results represent means  SD of six separate experiments 
in duplicate. IgG variation (VIgG) was obtained with the formula: 
VIgG  = (IgGx/IgGc)-1. 
 
3.5. Glycerol gradient sedimentation 
Aliquots of 300 l of cytosol were loaded on a 3.9 ml glycerol (10%-40%) linear 
gradient in 25 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, pH 7.4, 
1 mM ethylenediaminetetraacetic acid. The tubes were centrifuged 18 hours at 
100 000×g in an SW60Ti rotor (Beckman Coulter, Fullerton, CA) at 4°C and 
fractionated from the top into 18 fractions, and subjected to Western blotting 
analysis under denaturing conditions. Sedimentation markers run in parallel was 
formed by albumin (66 kDa), alcohol dehydrogenase (150 kDa) and amylase 
(200 kDa), apoferritin (443 kDa). 
 
3.6. Anti-MR immunoprecipitations (IP) 
Cytosol from untreated RBCs, obtained as described above was precleared with 
protein A-Sepharose, and then incubated for 5 h at 4°C with anti-MR antibody 
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bound to protein A-Sepharose. Immune complexes were washed three times in 50 
mM Tris–HCl pH 7.5, 1 mM vanadate and protease inhibitor cocktail, and 
subjected to Western blot analysis by immunostaining with anti-MR antibody 
(Santa Cruz). 
 
3.7. Anti-MR evaluation at confocal microscopy 
Aliquots of untreated purified RBCs were washed with PBS, fixed with 2% (w/v) 
paraformaldehyde and incubated on slides pre-coated with poly-L-lysine. Slides 
were rinsed twice with PBS, treated with Triton X-100 and incubated with anti-
MR in a humid chamber. Slides were washed three times with PBS, stained with 
anti-rabbit IgG- Tetramethyl Rhodamine Isothiocyanate (TRITC) conjugate in a 
humid chamber in the dark and mounted. Fluorescence was detected with the 
UltraView LCI confocal system (Perkin Elmer, Waltham, MA, USA). Staining 
without primary antibody was used as negative control. 
 
3.8. Quantitative determination of total glutathione 
content in RBCs cytosol 
Total glutathione in cytosol was determined according to the Tietze method 
(Tietze, 1979). Briefly, 10 l of cytosol from HC and PA RBCs or from in vitro 
samples, were added to 2 ml of reaction mixture containing 1.9 ml of phosphate 
0.1 M/ EDTA 0.6 mM buffer, pH 7.4, 30 l of 5,5’-dithio-bis(2nitrobenzoic acid) 
(DTNB) 10 mM, 100 l of NADPH 5 mM. After a 3 min equilibration period at 
room temperature, the reaction was started by the addition of 10 g glutathione 
reductase (GR). Product formation was recorded spectrophotometrically at 412 
nm, for 4 min at room temperature.  
To assess any impairment in the antioxidant capacity of the erythrocytes, we 
treated RBCs of HC, PA or in vitro samples with diamide, and analysed cytosol 
glutathione content. 
Previous study (Bordin et al., 2010b) demonstrated that after diamide treatment 
total glutathione in RBCs of patients with oxidative stress, dropped considerably 
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but did not significantly change in healthy controls. This suggested the hypothesis 
that the drop in total glutathione in patients was due to irreversible oxidation of 
glutathione, which remains bound to another protein, forming permanent 
disulphide bonds that GR could affect with minor efficacy.  
For this reason we calculated the total decrease in glutathione content after 
diamide treatment (GSH), expressed as 1-(GSH(D)/GSH(B)), GSH(D) being 
change of absorbance in the sample with diamide treatment and GSH(B) that in 
untreated cells. 
 
3.9. Determination of glutathione-protein mixed 
disulphide (GSSP) in RBCs 
GSSP determination was carried out as previously described (Di Simplicio et al., 
1998). Briefly, membranes, obtained as described above, were deproteinized by 
the addition of trichloroacetic acid (TCA) (5% final concentration) and kept on ice 
for 3 min. After centrifugation for 3 min at 16100×g, the pellet was resuspended 
with 0.4 ml basic solution containing 9 vol 0.1 M phosphate buffer (pH 7.4) and 1 
vol 0.25 N NaOH, and stirred for 30 min at room temperature. Thirty microliters 
of 60% TCA was then added to cause precipitation and the amount of released 
GSH was determined enzymatically in the supernatant of centrifuged samples (as 
described above). Under these conditions thiols bound by mixed disulfides are 
easily removed.  
The increase in glutathione released from membranes of RBCs after diamide 
treatment (D), representative of the increase in glutathionylated protein content 
(GSSP), was expressed as (GSSP(D)/GSSP(B))-1. 
 
3.10. Esterase activity assay 
The activity of carbonic anhydrase was assayed by following the change in 
absorbance at 348 nm of 4-nitrophenylacetate (NPA) to 4-nitrophenylate (PNP) 
ion over a period of 10 min at 25 °C with a spectrophotometer (CHEBIOS UV–
VIS) according to the method described by Verpoorte (Verpoorte et al., 1967). 
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Briefly, the enzymatic reaction was carried out in a total volume of 3.0 mL, 
containing 1.4 mL 0.05 M Tris–SO4 buffer (pH 7.4), 1 mL 3 mM NPA, 0.5 mL 
H2O and 0.1 mL diluted cytosol. A reference measurement was obtained by 
preparing the same cuvette with sample solution in the absence of incubation. 
One unit of CA activity was defined as the amount of enzyme which catalyses the 
formation of 1 pmol PNP/min in standard conditions of incubation. The mixture 
was incubated for 10 min at room temperature, and the following formula 
incorporating the extinction coefficient was used to calculate: CA units x10
-3
/ l 
packed RBCs = OD × sample dilution factor /(min × 667), with an extinction 
coefficient of 667. 
 
3.11. Tyr-protein kinase activity assays 
Tyr-phosphorylation assays of membrane proteins were performed by incubating 
RBCs membranes (10 µg) for 10 min at 30ºC in 30-µl reaction mixtures 
containing 50 mM Tris–HCl, pH 7.5, 10 mM MnCl2, 20 µM [γ-
33
P]ATP (3×10
6
 
cpm/nmol) and 0.1 mM vanadate and 200 µM cdc2 peptide, which served as 
specific substrates for Src family tyrosine kinases. Reactions were stopped by the 
addition of 2% SDS and 1% β-mercaptoethanol (final concentrations) incubated 
for 5 min at 100ºC, and analyzed by SDS- PAGE and revealed by a Cyclone 
Storage Phosphor Imager. (Tibaldi et al., 2008) 
 
3.12. Tyr-protein phosphatase activity assays 
Phosphatase activity was measured at 30°C using 10 nM nitrophenyl phosphate 
(pNPP) as substrate in 100 mM tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 
mM 2-mercaptoethanol, and samples membranes (10 µg). After 10 min at 30°C, 
the reaction was quenched with 950 μl of 1 M NaOH. Absorbance at 405 nm was 
measured. Results are expressed as percentage of activity compared to the 
controls. 
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3.13. Statistical analysis 
Data are expressed as means ± SD. Comparisons were obtained with Student’s t-
test and statistical significance was set at p<0.05 (two-tailed). Any relationships 
between pairs of variables were tested by least-squares linear regression. 
Pearson’s correlation coefficient r was used to quantify the strength of the 
relationships. The statistical significance of r was determined by ANOVA; a p 
value of less than 0.05 was considered statistically significant (two-tailed). 
Comparison between the slope of regression lines was performed with Student’s t-
test. 
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RESULTS 
1. PART 1: identification and characterization of 
the RBCs alterations in PA patients 
 
1.1. Evaluation of Band 3 Tyr-P level and HMWA 
content in PA patients 
To examine RBCs membrane status, diamide-related band 3 Tyr-P levels were 
determined in patients’ RBCs. Although in the absence of diamide stimulation 
Tyr-P could not be detected in RBCs from either controls or patients (Fig. 1A, 
lanes a, b), when PA RBCs were incubated with diamide, membranes showed 
higher band 3 Tyr-P levels in comparison with RBCs from HCs (Fig. 1A, lane d 
compared with lane c). 
 
 
 
Figure 1. Panel A: Tyr levels in healthy controls (HCs) (lanes a, c) and in patients 
with primary aldosteronism (PA) (lanes b, d). RBCs, isolated as described in Methods, 
were incubated in the absence (lanes a, b) or presence (lanes c, d) of 1.5 mM diamide. 
Membranes, obtained as described in Methods, underwent Western blotting and were 
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immunostained with anti-P-Tyr, or anti-actin antibodies as a loading control. The figure is 
representative of more than 12 separate experiments. 
Panel B: Linear regression between plasma Aldo and the band 3 Tyr-P level (after 
diamide treatment) (C) or HMWA formation (in the absence or presence of diamide 
treatment) (D). The Tyr-P value of diamide-treated RBC was calculated as the ratio to the 
Tyr-P level of diamide-treated RBC obtained in HCs (chosen as arbitrary comparison 
unit, experimentally determined as 99±2 mean value±SD). 
 
 
Due to the wide range of the values obtained by the densitometrical evaluation of 
the band 3 Tyr-P levels in PA RBCs (Fig. 1A, Tyr-P increase of 93±43 %,  
p<0.001), we analyzed PA patients on the basis of their Aldo plasma level and a 
significant correlation (r=0.9640, p<0.0001) was found between plasma content of 
Aldo and band 3 Tyr-P level (Fig. 1B). 
This Aldo-related increased response to diamide was further investigated by 
analyzing RBCs membrane status. Band 3 aggregates in high molecular weight 
(HMWA) complexes in a way that is directly dependent to the redox state of the 
cells (Bordin et al., 2010a; Bordin et al., 2006). 
In Fig. 2 we reported band 3 HMWA pattern of membranes from PA patients 
(panel A, lanes a, b) and HCs (lanes c, d). Interestingly, PA patients (lane a) 
clearly showed higher HMWA content compared to HCs (lane c), even in the 
absence of diamide. Diamide addition induced further aggregation of band 3 both 
in PA patients (lane b) and in HCs (lane d) as expected due to diamide-induced 
disulfide bond formation between cysteine residues of band 3 (Lutz et al., 1988). 
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Figure 2. Panel A: Band 3 HMWA contents in PA patients (lanes a, b) and in HCs 
(lanes c, d). RBCs, isolated as described in Methods, were incubated with (lanes b, d) and 
without (lanes a, c) diamide. RBCs membranes, underwent Western blotting in non-
reducing conditions, and were revealed with anti-band 3 antibodies. The figure is 
representative of 12 separate experiments.  
Panel B: The HMWA values of both diamide treated (+Diam) and untreated (-Diam) 
RBCs from patients with PA were obtained as the ratio to the HMWA content of RBCs 
from HCs, respectively, in the presence or absence of diamide (chosen as arbitrary 
comparison units). 
 
 
Upon densitometric analysis of HMWA content, a significant correlation with the 
plasma Aldo content of patients with PA (Figure 2B) was detected, both in the 
absence or in the presence of diamide (r=0.8596, p<0.0005 and r=0.7474, 
p<0.005, respectively). The slope of the 2 regression lines was not statistically 
different (p=0.6862), indicating that the 2 lines are parallel, thus confirming that 
both in the absence and presence of diamide, a similar correlation between plasma 
Aldo and HMWA content exists. 
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1.2. Evaluation of Aldo effects on Band 3 Tyr-P level 
and HMWA content in HC RBCs in in vitro 
treatments 
To better evaluate whether the alterations seen in RBCs from patients with PA 
were due to increased plasma Aldo concentrations, we performed in vitro 
experiments with blood from HCs. As described in Methods, RBCs were pre-
incubated for 1 hour or 24 hours at 35°C in CS-PPP or PPP with increasing Aldo 
concentrations, Can (1 µM), Cort (5 µM), both Aldo (5 nM) and Can (1 µM), or 
both Aldo (5 nM) and Cort (5 µM) and successively incubated in the presence or 
absence of 1.5 mM diamide. Membranes were analyzed by Western blotting with 
appropriate antibodies, and immunostained blots were evaluated 
densitometrically. 
The band 3 Tyr-P level (Fig. 3) in RBCs pretreated in PPP 0 (0 nM Aldo), ie, in 
the absence of Aldo and other hormones, was chosen as a reference value for the 
PPP treatment and represented HCs conditions. Addition of increasing Aldo 
concentrations resembled RBCs environments in patients with PA. Can or Cort 
was added as an Aldo competitor. Samples incubated for 1 hour with PPP showed 
no detectable Tyr-P level in the absence of diamide. When added to PPP-
pretreated RBCs, diamide triggered band 3 Tyr-P with an Aldo dose and time-
dependent increase, peaking at 5 nM Aldo and rapidly decreasing at 10 nM, with a 
rise of band 3 Tyr-P ranging from 4±7 (1 hour) to 27±3 (24 hours) of band 3 Tyr-
P variation (VTyr-P, see legend of Fig. 3), compared with the control (ie, in absence 
of Aldo). When RBCs pretreatment was performed with either Can or Cort in the 
absence of Aldo, band 3 Tyr-P level induced by diamide was not affected and 
remained at control levels. However, when pretreatment with Aldo (5 nM) was 
performed in the co-presence of Can or Cort, the consequent diamide-induced 
band 3 Tyr-P level was significantly reduced compared with the peak obtained 
with 5 nM Aldo (VTyr-P of 8±3 and 3±3 for Can and Cort, respectively, at 24 
hours).  
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Figure 3. Effect of Aldo and 1 µM canrenone (Can) or 5 µM cortisol (Cort) on RBC 
Tyr-P in non-stripped (PPP) or charcoal-stripped (CS-PPP) plasmas at 1 and 24 
hours of incubation.  Data, expressed as variation compared with the respective controls 
in the absence  of Aldo, Can, or Cort, are the mean±SD of 6 different experiments in 
duplicate. VTyr-P is the band 3 Tyr-P variation, evaluated densitometrically. To better 
appreciate the variations obtained in different samples, we evaluated the Tyr-P level in 
relation to the corresponding controls (absence of Aldo). Therefore, the Tyr-P value of 
diamide-treated RBC from Aldo- Can-, and Cort-treated or co-treated samples (Tyr-PX) 
was calculated as the ratio to the correspondent Tyr-PC, ie, the Tyr-P level of diamide-
treated RBCs obtained in PPP 0 (0 nM Aldo) or in CS-PPP 0, according to the following 
formula: VTyr-P =(Tyr-PX/Tyr-PC)-1. 
* p<0.05; *** p<0.001, comparison between 1 and 24 hours.  
† p<0.05; †† p<0.01; ††† p<0.001, comparison with the respective basal value (Aldo 0 
nM).  
a p<0.001, comparison of (5 nM Aldo) vs (5 nM Aldo+Can), or (5 nM Aldo) vs (5 nM 
Aldo+Cort), within each respective experimental condition. 
 
 
To ascertain that the effects shown with Aldo pretreatment were effectively due to 
Aldo, we incubated RBCs in CS-PPP, ie, in plasma stripped of steroid hormones. 
Diamide addition to CS-PPP RBCs pretreated with increasing concentrations of 
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Aldo induced high Tyr-P, peaking at 5 nM and resembling those reported for 
patients with PA (Fig. 1B). In fact, 5 nM Aldo pretreatment-induced VTyr-P was 
about 17±5 after 1 hour (p<0.001), but reached 120±10 after 24 hours (p<0.001) 
(Fig. 3). Interestingly, in this case also, further increasing the Aldo concentration 
to 10 nM induced a reduction in the extent of the Tyr-P level. When Aldo was 
replaced by Can or Cort, the diamide-induced band 3 Tyr-P level remained at the 
control level and when 5 nM Aldo was added in association with Can or Cort, 
diamide- P-Tyr levels were strongly reduced.  
 
The HMWA content of RBCs incubated with Aldo in PPP in the absence of 
diamide reached an VHMWA of 11±5 (at 1 hours) and 23±3 (at 24 hours), compared 
with the control (absence of Aldo pretreatment) (Fig. 4). Can or Cort did not 
induce any alteration in the above parameters, but when added with Aldo 
prevented Aldo-related effects. Interestingly, no decrease was shown by further 
increasing the Aldo concentration to 10 nM, either at 1 hour or 24. When HMWA 
formation was evaluated after CS-PPP pretreatment with increasing Aldo 
concentrations, a dose- and time-dependent effect of Aldo was seen, peaking at 5 
nM with a maximal VHMWA never exceeding 21±3 after 1 hour (p<0.001) and 
63±3 after 24 hours (p<0.001) and followed by a slight decrease at 10 nM at both 
incubation times.  
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Figure 4. Effect of Aldo, 5 µM canrenone (Can) or 5 µM cortisol (Cort) on band 3 
high molecular weight aggregates (HMWA) and IgG binding in in non-stripped 
(PPP) or charcoal-stripped (CS-PPP) plasmas. Data, expressed as variations compared 
with the respective control incubated in the absence of Aldo, Can, or Cort, are the 
means±SD of 6 different experiments in duplicate.  
HMWA variation (VHMWA): Membranes (1 µg) from RBCs treated for 1 hour or 24 
hours with Aldo, 1 µM Can, or 5 µM Cort in PPP or CS-PPP, were analyzed by SDS-
PAGE (8%) in non-reducing conditions and immunostained with anti-band 3 antibody 
and bands were scanned densitometrically. The amount of band 3 HMWAs in 
unstimulated conditions (HMWAC: Aldo 0 in PPP, at 1 h) was arbitrarily chosen as unity. 
The formula for VHMWA calculation was VHMWA=(HMWAX/HMWAC)-1. 
* p< 0.05; ** p< 0.01; *** p<0.001, comparison with the respective basal value (0 nM 
Aldo). 
b p< 0.01; a  p< 0.001, comparison (5 nM Aldo) vs (5 nM Aldo+Can) or (5 nM Aldo) vs 
(5 nM Aldo+Cort), within each respective experimental condition. 
 
 
To evaluate the possible involvement of Aldo pre-incubation in altering RBCs life 
span, membranes obtained from the samples described above were analyzed for 
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their IgG content (Fig. 5). In this case also, Aldo pretreatment induced a marked 
increase in autologous IgG binding, plateauing at 5 nM in both PPP and CS-PPP 
samples, which was completely prevented by Can or Cort co-addition. 
 
 
Figure 5. Effect of Aldo, 5 µM canrenone (Can) or 5 µM cortisol (Cort) on IgG 
binding in in non-stripped (PPP) or charcoal-stripped (CS-PPP) plasmas. Data, 
expressed as variations compared with the respective control incubated in the absence of 
Aldo, Can, or Cort, are the means±SD of 6 different experiments in duplicate.  
IgG variation (VIgG): Membranes (8 µg) from RBCs treated for 24 hours with Aldo, 5 
µM Can, or 5 µM Cort in PPP or CS-PPP were analyzed by SDS-PAGE (8%) and 
immunostained with anti-human IgG antibody and bands were densitometrically scanned. 
The amount of IgG in Aldo 0 in PPP (IgGC) was chosen as an arbitrary unit. VIgG was 
obtained with the formula: VIgG= (IgGX/IgGC)-1. 
** p< 0.01; *** p<0.001, comparison with the respective basal value (0 nM Aldo). 
a  p< 0.001, comparison (5 nM Aldo) vs (5 nM Aldo+Can) or (5 nM Aldo) vs (5 nM 
Aldo+Cort), within each respective experimental condition. 
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2. PART 2: ALDO-MR PATHWAY 
2.1. MR detection in human RBCs cytosol 
In the first part of the study it has been hypothesized that Aldo affected 
membranes through a pathway involving MR, due to the inhibitory effect of Can 
that almost completely prevented Aldo-induced membrane alterations. To 
investigate the presence of MR, both cytosol and membranes of HC RBCs were 
analyzed by Western blotting and revealed with anti-MR antibodies (Fig. 6, panel 
B). 
Immunodetection showed bands at 100, 80, 50-53 and additional bands at 20-25 
kDa in cytosol (lane b) but when membranes were analyzed, no trace was evident 
(lane a). 
RBCs immunocytochemistry analysis with anti-MR (MCR H-300) antibodies 
revealed homogeneous diffuse fluorescence, confirming the presence of the 
receptor within the cell (panel A). 
Due to the fact that the aggregation of steroid receptors in multiprotein complexes 
generally involves the chaperone protein HSP90 (Mjahed et al., 2012), we 
analyzed its potential presence in the cytosol of human RBCs. Immuno-blotting 
with anti-HSP90 antibodies confirmed that HSP90 was present in both cytosol 
(panel C, lane a) and, although partially proteolysed, also in membranes (lane b). 
Interestingly, anti-MR IP also exhibited a consistent band of anti-HSP90, co-
immuno-precipitating with MR (lane c). 
These results prompted us to separately investigate cytosol and membranes to 
better understand the mechanism of action and regulation of MR in the cytosol 
and the related pathway leading to membrane alterations. 
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Figure 6. Identification and localization of mineralocorticoid receptor (MR) in 
human RBCs. Panel A: Anti-MR detection by immunofluorescence cytochemistry of 
untreated RBCs from healthy controls (HCs); corresponding phase-contrast images are 
shown. Panel B: Anti-MR Western blotting. Untreated RBCs from HCs, isolated as 
described in Methods, underwent haemolysis. Membranes (lane a) and cytosol (lane b) 
obtained as described in Methods, underwent Western blotting and were immunostained 
with anti-MR antibody. Panel C. Anti-HSP90 Western blotting. Cytosol (lane a), 
membranes (lane b) and anti-MR immunoprecipitate (MR-IP, lane c) obtained from 
cytosol were analysed by  Western blotting and immunorevealed with anti HSP90 
antibody. The figure is representative of five separate experiments. 
 
 
2.2. MR gradient sedimentation in human RBCs 
cytosol: MR activation by Aldo 
After RBCs hemolysis, cytosol was further processed by glycerol gradient 
sedimentation, and sedimentation profiles were analysed by Western blotting to 
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ascertain whether MR was present as a monomer or a dimer/polymer (Fig. 7). In 
the control C, RBCs cytosol immunodetection with anti-MR showed that MR was 
stratified into a large number of glycerol fractions, from 3 to 10, i.e., over a wide 
range of molecular weights, probably due to its interaction with other proteins. In 
addition, within each fraction, MR itself was present as different isoforms, 
simplified in two main regions: one, at 20-25 kDa (panel B) involved two bands 
which were more evident in fractions 4-6 (corresponding to glycerol 
sedimentation weight ranging from about 80 to 130 kDa); and the other involving 
bands from 50 to 80 kDa (panel A), visible only from fraction 5 to 10 
(corresponding to the 100-400 kDa range of sedimentation weights). In fractions 
5-7 only bands of 50-53 kDa were well distinguishable; in fractions 8-10, a new 
band at about 60 kDa appeared but those at 50-53 kDa disappeared (panel A, 
sample C). 
The addition of 5 nM Aldo induced net rearrangement of the band at 60 kDa, 
which almost disappeared from fractions 8-10, whereas the 50-53 kDa band 
increased in fractions 4-9 (Fig. 7, panel A sample C compared with sample Aldo). 
Concomitantly, Aldo also induced the appearance of the 80 kDa isoform in 
fractions 5-7 and shifting of the 20-25- kDa bands from fractions 4-6 in sample C 
to fractions 3-6 in sample Aldo (Fig. 7, panel B). 
Surprisingly, when the same fractions were immuno-detected with anti-MR (MA 
1-620) antibody produced with aldosterone-3 as immunogen, MR was detected 
only in fractions 6-10, whereas no trace was appreciable in the other fractions, in 
either C or Aldo samples (not shown). This discrepancy with MR (MCR H-300) 
detections (Fig. 7) suggests that Aldo-MR binding is not reversible since Aldo 
remains entrapped in the MR pocket even after MR proteolysis and the complex 
Aldo-MR is no longer detectable by MA 1-620 antibody, as indicated by the 
corresponding datasheet (not shown). 
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Figure 7. MR gradient sedimentation. RBCs from 12 healthy volunteers, purified as 
described in supplementary section methods, were incubated at 37
°
C for 1h in absence 
(C) or presence of 5 nM aldosterone (Aldo) or 5 M cortisol (Cort) in charcoal-stripped 
plasma to remove small molecular weight macromolecules such as steroid and peptide 
hormones. Incubated RBCs were hemolysed and 300 l of diluted cytosol was loaded on 
top of a linear glycerol gradient and centrifuged for 18 hours at 100 000×g. Eighteen 
fractions (200 μL each) were collected from top, analysed by Western blotting and 
immuno-detected with anti-MR antibody (MCR H-300) raised against aminoacids 1-300. 
Panels A and B: bands corresponding to 50-80- and 20-25-kDa regions of gels. Data are 
means ± SD of duplicate measurements from 12 healthy volunteers. Densitometric 
analysis of anti-MR Western blots of 50-80- and 20-25-kDa bands (panels A and B, top 
panels) were quantified; data are expressed as % of total amount of 50-80- or 20-25-kDa 
bands, respectively, in all fractions, according to MR-bandsfraction/MR-bandstotal. 
Statistical analysis showed significant difference at peak values between control and Aldo 
conditions (‡  p<0.0001, ANOVA, comparison C vs Aldo). 
Arrows at the bottom of panels: position of molecular weight standards on glycerol 
gradients, albumin (66 kDa), alcohol dehydrogenase (150 kDa), -amylase (200kDa) and 
apoferritin (443 kDa), to estimate molecular weight of protein complexes on parallel 
gradient runs. 
 
Densitometrical analysis of the bands in the 50-80 kDa region (panel A diagram) 
of C sample peaked in fractions 7-10. The same MR isoforms as in the Aldo 
sample (dotted lines) were shifted to fractions 5-8, whereas Cort did not induce 
any change in the location of the MR peak which remained similar to that of 
controls. These results showed that Aldo treatment induced MR to break away 
from the multiprotein complex, and MR dimers were formed, as indicated by the 
appearance of 80-kDa bands in the region of 90-170 kDa range of the gradient. In 
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addition, the increase in low molecular weight bands (20-25 kDa) in fractions 3-6 
(panel B) showed the degradation of MR (again demonstrated by a shift of peak 
position) triggered by treatment with Aldo, but not by Cort. 
The addition of Can, either alone or in association with Aldo, did not alter the MR 
situation, which was similar to that of controls (data not shown). Similar results 
were obtained when RBC were co-treated with Aldo and Cort (data not shown). 
When Western blotted glycerol fractions were immuno-detected with anti-HSP90 
antibodies, a major band at 90 kDa and a proteolysed isoform of about 60 kDa 
were mainly sedimented  in fractions 6-10. Other treatments did not induce 
appreciable movements of trend-lines compared with controls (data not shown). 
 
2.2.1. Effect of Aldo or Cort on MR fragmentation 
The presence of low molecular bands (20-25 kDa) raised the possibility that a 
proteolytic process regulates the MR pathway. Low weight MR bands were 
collected in a large number of fractions (3-9), suggesting that the 20-25 kDa 
isoforms were both part of multi-complex proteins (fractions 8-10) or derived 
from a single monomer of MR (fractions 3-5). In addition, a band of less than 10 
kDa was found in C samples from fractions 4-7, suggesting the occurrence of 
further proteolytic digestion mainly in the monomeric and dimeric forms of MR 
(data not shown). 
Glycerol gradient fractions were thus analyzed by Western blotting in non-
reducing conditions to highlight any fragments broken away from the multi-
protein complex. Figure 8 compares the anti-MR patterns obtained with non-
reducing (NR) Western blotting of Aldo- and Cort-treated samples. Anti-MR 
bands at 50-60 kDa, present in fractions 5-10 of reducing (R)-WB (Fig. 7, panels 
A), were no longer be detected, whereas two sets of bands were evidenced. The 
first showed a band at high molecular weight (HMW) which did not change in any 
of the conditions (data not shown) and the second set was composed by bands 
corresponding to 20-25 and < 10 kDa bands (Fig. 8, panels A and B). Aldo 
induced both the formation of bands in the region  ≤ 25 kDa in fractions 3-4 and 
net shifting of bands <10 kDa to fractions 3-8. Cort did not affect the number of 
low- weight bands which remained at the level of controls (panel B). 
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Figure 8. RBCs from 12 healthy volunteers, incubated at 37
°
C for increasing times (10, 
30, 45, 60 min) in absence (C) or presence of 5 nM aldosterone (Aldo) or 5M cortisol 
(Cort), were hemolysed and 300 l of diluted cytosol were loaded on top of a linear 
glycerol gradient and centrifuged for 18 hours at 100 000×g. Fractions (200 μL each) 
from top were analysed by Western blotting in non-reducing conditions and immune-
detected with anti-MR antibody. Panels A and B: bands corresponding to 20-25 and <10 
kDa regions of gels of samples Aldo and Cort incubated for 60 min.  
Panels C and D: values from samples incubated for increasing times with Aldo and Cort. 
Bands were densitometrically analysed and compared with corresponding controls: 
highest band in C for each molecular weight region was taken as comparison unit. Same 
fraction as in C containing  highest band was considered as comparison in other samples.  
*: values significantly different between C and 60-min curves (ANOVA, p<0.001). 
 
The intriguing involvement of a proteolytic process degrading MR after addition 
of Aldo but not of Cort was further investigated in experiments carried out at 
increasing incubation times. 
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Samples were treated in the absence (C) or presence of Aldo or Cort for 10, 30, 45 
and 60 min and cytosols were analyzed by glycerol gradient sedimentation. In the 
NR-WB of fractions MR bands corresponding to 20-25 and <10 kDa which were 
densitometrically evaluated and separately counted and reported in panels C 
(Aldo) and D (Cort). Aldo addition resulted in time-dependent MR fragmentation 
starting from the first 10 min of incubation in both 20-25 and <10 kDa regions. 
Interestingly, in the Cort-treated samples, MR only showed a slight shift to 
fraction 3 of the proteolytic fragments. When bands at 50-80 kDa were examined 
in R-WB (not shown) Cort induced a light shifting to fractions 3 and 4 in the first 
10 min but, after 60 min MR bands were recovered in the same fractions as the 
control, as if re-adjustment of Cort-MR were compatible with re-aggregation of 
MR in the multi-protein complex. Conversely, Aldo effect confirmed a time-
dependent shift to the first fractions. 
 
2.2.2. MR association in multiprotein complexes 
Further study of MR-multiprotein complex dissociation was carried out in the 
cytosol of untreated RBC and fractions 8-10 from the glycerol gradients were 
pooled. In these fractions, MR was part of the multi-protein complex and present 
in the highest isoforms (Fig. 7, panel A). The pooled fractions were then divided 
into five aliquots and treated at 0°C for 30 min in the absence (controls) (Fig. 9, 
panel A, lane a) or presence of 5 M Cort (lane b), 1 M Can (lane c), 2 or 5nM 
Aldo (lanes d and e) in order to allow the ligands to bind to the receptor, which 
was then immuno-precipitated by the addition of anti-MR. MR-immuno-
precipitates (IP) from control- and Can- treated aliquots only showed traces of 
MR (lanes a, c), as revealed by WB with anti-MR antibody (MCR H-300). In the 
Cort-treated aliquot, the MR band was more than three times that of the control 
(+315% lane b vs lane a, p<0.0001) whereas Aldo treatment induced a dose-
dependent decrease in the MR-IP band (-25 and -55%, lanes d and e, respectively, 
vs lane a, p<0.0001). To better characterize the complex ligand-receptor, 
supernatant recovered from the previous IP were re-immuno-precipitated (Re-IP) 
in the presence of DTT, a reducing agent, and immuno-detected with anti-MR 
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(panel B: Re-IP). The amount of MR recovered from Aldo-treated samples 
increased greatly compared with that recovered from the control (+30 and +60 % 
lanes d and e, vs lane a, p<0.0001), whereas from the Cor- treated sample the Re-
IP MR band was -90% (lane b; p<0.0001) compared with controls. Re-IP from 
Can-treated samples yielded the same band as controls (lane c vs lane a). 
 
 
Figure 9. Fractions 8-10 from the C sample glycerol gradients were collected, divided 
into 5 aliquots and treated at 0°C for 30 min in absence (control) (lane a) or presence of 5 
M Cort (lane b), 1 M Can (lane c), 2 or 5 nM Aldo (lanes d and e). Panel A: MR was 
then immunoprecipitated by anti-MR (MCR H-300) and MR-IPs were analysed by 
Western blotting with anti-MR antibody. Panel B: supernatants recovered after MR-IP as 
described above were re-immunoprecipitated in presence of 5 mM dithiothreitol (DTT) 
and MR-IPs were analysed by Western blotting with anti-MR antibody. Panel C: 
fractions 8-10 from C sample glycerol gradients were collected, divided into 5 aliquots 
and treated at 0°C for 30 min with Gelda 100 nM in absence (control) (lane a) or presence 
of 5 M Cort (lane b), 1 M Can (lane c), 2 or 5nM Aldo (lanes d and e). MR was then 
immunoprecipitated by anti-MR (MCR H-300) and MR-IPs were analysed by Western 
blotting with anti-MR antibody.Bands were densitometrically analysed and reported on 
the right of the corresponding panel. 
* p<0.0001 vs control (lane a). 
 
DTT induced increase in further MR re-immuno-precipitations from almost all 
samples, except Cort-treated ones, is due to the fact that the N terminal (1-300) 
region of MR, recognized by the antibody, was involved in dimer/complex 
formation, thus preventing MR immuno-precipitation. The decrease of MR-IP in 
Aldo-treated samples was due to Aldo-MR dimer formation, as shown by the 
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shifting of the MR-recovering curve in glycerol gradient sedimentation (Fig. 7). In 
the MR dimer, binding was more stable than in the complex (Fig. 9, lane a), 
meaning that the antibody was less capable of recognizing the N-terminal region 
compared with controls. Instead, Cort treatment induced MR release from the 
complex but not dimer formation, thus making the MR-N-terminus recognizable 
by the antibody. Reducing conditions may dissociate MR from both dimer and 
complex, as indicated by the increase in the MR-band in Re-IP assays of controls 
and Aldo-treated samples (Fig. 9, panel B, lanes a, d, e). Can did not alter the 
structure of the MR-complex, which remained at control level. 
For further confirmation, the addition of Geldanamycin (Gelda), an apoptotic 
compound which inhibits HSP90 and disrupts the cytosol-multiprotein complex 
(Stebbins et al., 1997), prevented Aldo-induced dimer formation, as demonstrated 
by complete recovery of MR from all samples (panel C, lanes a-e) and the absence 
of MR in the Re-IP assay in reducing conditions (data not shown).  
 
2.2.3. MR-complex involvement in Aldo signaling 
When HC RBCs were pre-incubated in CS-PPP in the presence of Geldanamycin 
and successively incubated with Aldo, both HMWA formation (data not shown) 
and IgG binding were completely prevented (Fig. 10, lane e compared to lane d), 
thus confirming the involvement of HSP90 in the maintaining the correct MR 
conformation for Aldo binding and the successive MR activation.  
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Fig. 10. IgG binding to RBCs membrane. HC RBCs were pre-incubated (20 min at 
37°C) in CS-PPP in absence (lanes b, d and f) or presence of Geldanamycin (lanes c, e 
and g) and successively incubated at 37°C for 1 h, without (lanes b and c) or with 5 nM 
Aldo (lanes d and e) or 5 µM Cort (lanes f and g). After incubation, all samples were 
haemolysed in hypotonic buffer. Membranes of HC RBCs, washed and haemolysed 
without incubation, were used as negative control (lane a). RBCs membranes (2 µg), 
obtained as described in Methods, were then analysed by SDS-PAGE (8%) and 
immunostained with anti-Human IgG antibody and anti-actin, as loading control. 
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3. PART 3: Partial characterization of the Aldo-
induced alterations in PA RBCs 
 
3.1. Parameters of the cellular oxidative status  
Due to the evidence that Aldo induced membrane alterations leading to band 3 
HMWA formation and diamide-induced high Tyr-P level are similar to those 
previously reported in inflammatory related increased oxidative stress conditions 
(Bordin et al., 2010b; Donà et al., 2012), HC and PA RBCs membranes were 
analysed by Western blotting and immuno-revealed with anti-GSH antibody (Fig. 
11 and Table 1). Significantly, no difference was evident between PA and HC 
RBCs membranes.  
 
 
Figure 11. Panel A: GSH in RBCs membrane from HC, PA and In vitro samples. 
RBCs were isolated from fresh blood collected from controls (HC) (n=12) and patients 
(PA) (n=22) and isolated as described in Methods. For in vitro treatment, only blood from 
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HC was utilized, and RBCs, were incubated at 37°C for 1h in absence (C) or presence of 
5 nM aldosterone (Aldo) or 5 µM cortisol (Cort) or both (Aldo+Cort), in charcoal-
stripped plasma to remove small molecular weight macromolecules such as steroid and 
peptide hormones. Membranes (10 g), obtained as described in Methods, underwent 
Western blotting in non-reducing conditions and were immunostained with anti-GSH 
antibody, or anti-actin antibody as loading control. Figure is representative of the study 
population. 
Panel B: Determination of glutathione-protein mixed disulfide (GSSP) in RBCs. 
Membranes, obtained from HC, PA and In vitro samples (C, Aldo, Cort and Aldo+Cort) 
as described in Methods, were TCA-deproteinized and alkalinized, and the amount of 
GSH released from proteins was determined enzymatically in the supernatants, as 
described in Methods. 
The increase in glutathione released from RBCs membranes after diamide (1.5 mM) 
treatment, representing increase in glutathionylated protein content (GSSP), is expressed 
as (GSSP(D)/GSSP(B))-1. 
Data show the means ±SD. Comparison HC vs PA and for in vitro experiments, C vs 
Aldo, Cort and Aldo+Cort. Student’s t test  reveals no statistical significance. 
 
This result was further investigated by extracting the total glutathione bound to 
the membrane proteins (GSSP). No detectable difference in the content of GSSP 
was present between the two groups. Diamide treatment has been shown to 
emphasize eventual pre-existent alterations related to an enhanced oxidative status 
by increasing the amount of GSH irreversibly bound to membranes (Donà et al., 
2012; Andrisani et al., 2014). The difference between GSH contents in the 
absence and presence of diamide (GSSP) was representative of the redox state of 
membranes (Donà et al., 2012). When analysed for GSSP, no variation in the 
content of GSH bound to membrane proteins was evidenced, thus confirming that 
both HC and PA membranes shared the same redox conditions (Table 1). 
Concomitantly GSH content was evaluated also in the cytosol in absence and 
presence of diamide, and the relative GSH calculated. Also cytosol showed no 
alteration in the redox state (Table 1). 
To characterize the effect of Aldo while avoiding the potential interference of 
other circulating steroid hormones, plasma was treated overnight with charcoal, 
which can bind and strip steroids and other small molecules (Bordin et al., 2013). 
RBCs were then pre-incubated for 1h at 37°C in charcoal-stripped (CS-PPP) 
plasma with 5 nM Aldo, 5 M Cort, 1 M Can, alone or in association (Aldo and 
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Cort, or Aldo and Can), and cytosol and membranes recovered as described in 
Methods. 
As indicated in Table 1, also in in vitro experiments, Aldo did not induce any 
increase in protein glutathionylation of membrane, nor in the redox state as 
indicated by the GSSP (Donà et al., 2012). When cytosol was analysed for GSH 
and GSSG content, no alteration was induced by Aldo treatment, thus confirming 
that Aldo-induced alterations were not mediated by oxidative assault involving 
GSH dependent defense. 
 
Samples 
ΔGSH ΔGSSP 
HC 0.09±0.03 0.08±0.03 
PA 0.11±0.02 0.1±0.03 
    
In
 v
it
ro
 
C 0.1±0.04 0.09±0.04 
2 nM Aldo 0.08±0.03 0.12±0.02 
5 nM Aldo 0.09±0.02 0.11±0.02 
5 µM Cort 0.11±0.02 0.08±0.04 
Aldo + Cort 0.08±0.04 0.11±0.03 
1 µM Can 0.07±0.02 0.09±0.03 
Aldo + Can 0.1±0.03 0.11±0.02 
 
Table 1. Determination of GSSP, GSH in HC, PA and in vitro treated RBCs. 
Fresh blood was collected from HC and PA. For in vitro treatment, only blood from HC 
was utilized, and RBCs, were incubated at 37°C for 1h in absence (C) or presence of 2 or 
5 nM aldosterone (Aldo) or 5 µM cortisol (Cort) or 1 µM canrenon (Can), alone or in 
association (Aldo+Cort or Aldo+Can), in charcoal-stripped plasma to remove small 
molecular weight macromolecules such as steroid and peptide hormones. After 
incubation, RBCs underwent hemolysis in hypotonic buffer.  
GSSP: Membranes, obtained from HC, PA and In vitro samples as described in 
Methods, were TCA-deproteinized and alkalinized, and the amount of GSH released from 
proteins was determined enzymatically in the supernatants, as described in Methods. The 
increase in glutathione released from RBCs membranes after diamide (1.5 mM) 
treatment, representing increase in glutathionylated protein content (GSSP), is expressed 
as (GSSP(D)/GSSP(B))-1. 
GSH: 10 l of cytosol, obtained from HC, PA and In vitro samples as described in 
Methods, were analysed. Total glutathione was determined enzymatically and analysed 
spectrophotometrically at 412 nm. The total decrease in glutathione content after diamide 
treatment (GSH) was expressed as 1-(GSH(D)/GSH(B)), being GSHD glutathione content 
after diamide treatment and GSHB that in untreated cells. 
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Being GSH only a part of the antioxidant defenses of the cell, cytosol was also 
investigate for CA activity and monomerization, both factors particularly sensitive 
to the oxidative state of the cell (Andrisani et al., 2014).  
CA is a family of metallo-enzymes which catalyse the conversion of CO2 to 
HCO3
-
 and H
+
, and is involved in many physiological processes such as acid–base 
balance homeostasis, respiration, carbon dioxide and ion transport, and bone 
resorption (Henry, 1996; Sly and Hu, 1995). This enzyme was also relevant for its 
sensitiveness to an increased oxidative status. In fact, when cytosol from untreated 
HC RBCs was analysed for CA detection by Western blotting (Fig. 12 A) and 
activity (Fig. 12 B) in the absence (lane a) or presence of 1.5 mM diamide for 10 
(lane b) or 20 min (lane c), CA, present as dimer at 60 kDa, was shown to 
monomerize in time-dependent way and to increase its catalytic activity up to nine 
folds.  
 
 
Figure 12. Panel A: Diamide-induced CA monomerization in HC RBCs cytosol. Fresh 
blood was collected from HC RBCs, isolated as described in Methods, and incubated with 
and without 1.5 mM diamide for 10 or 20 min. Diluted cytosol, obtained as described in 
Methods, underwent Western blotting in non-reducing conditions and was 
immunostained with anti-CA antibody.  
Panel B: CA activity from 300 l of diluted cytosol from HC RBCs incubated with and 
without 1.5 mM diamide for 10 or 20 min. CA activity calculated as ratio to activity 
observed in untreated cells (chosen as arbitrary comparison unit, experimentally 
determined as 1±0.21, mean value ± SD). Data show the means±SD of n=12 separate 
experiments.  
* p<0.0001, comparison of CA activity, before and after diamide treatment, Student’s t-
test. 
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This was further confirmed in the previous study with endometriotic patients (EP) 
showing a net increase in CA activity compared to healthy controls (Andrisani et 
al., 2014). In this case, EP RBCs were also characterised by high degree of 
membrane glutathionylation and cytosolic GSH decrease, both parameters of a 
remarkable oxidative stress (Andrisani et al., 2014). 
This analysis was extended to HC, PA and in vitro treated RBCs. No variation 
was found between HC and PA, nor in the differently in vitro treated HC RBCs 
(Table 2). 
 
          
 
Carbonic anhydrase 
Samples 
Activity 
(mUnits /µl 
packed RBC) 
30 KDa % 60 KDa % 
HC 0.21±0.04 14±2 86±2 
PA 0.22±0.03 17±6 83±6 
     
In
 v
it
ro
 
C 0.19±0.06 15±3 85±3 
2 nM Aldo 0.20±0.05 16±2 84±2 
5 nM Aldo 0.18±0.05 18±4 82±4 
5 µM Cort 0.20±0.03 16±3 84±3 
Aldo + Cort 0.19±0.07 19±2 81±2 
1 µM Can 0.22±0.4 15±3 85±3 
Aldo + Can 0.17±0.07 13±3 87±3 
     Table 2. Determination of CA content and activity in HC, PA and in vitro treated 
RBCs. Fresh blood was collected from HC and PA. For in vitro treatment, only blood 
from HC was utilized, and RBCs, were incubated at 37°C for 1h in absence (C) or 
presence of 2 or 5 nM aldosterone (Aldo) or 5 µM cortisol (Cort) or 1 µM canrenone 
(Can), alone or in association (Aldo+Cort or Aldo+Can), in charcoal-stripped plasma to 
remove small molecular weight macromolecules such as steroid and peptide hormones. 
After incubation, RBCs underwent hemolysis in hypotonic buffer.  
CA content in RBCs cytosol: Diluted cytosol from 1 l of packed cells, obtained as 
described in Methods, underwent Western blotting in non-reducing conditions and was 
immunostained with anti-CA antibody. Densitometrical analysis of cytosol CA bands in 
HC, PA and in vitro samples RBCs was performed. Sum of 30 and 60 kDa bands 
arbitrarily calculated as 100%, taking into account that amount of proteolytic 30 kDa 
bands accounts for half the larger bands.  
CA activity: 300 l of diluted cytosol from RBCs of HC, PA and in vitro samples were 
analysed. The activity of carbonic anhydrase was assayed spectrophotometrically as 
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described in Methods. One unit of CA activity was defined as the amount of enzyme 
which catalyzes the formation of 1 pmol PNP/min in standard conditions of incubation. 
The mixture was incubated for 10 min at room temperature, and the following formula 
incorporating the extinction coefficient was used to calculate: CA Units x10
-3
/ µl packed 
RBCs = OD × sample dilution factor /(min × 667), with an extinction coefficient of 667. 
Values expressed as means±SD. Comparison HC vs PA and for in vitro experiments, C 
vs Aldo, Cort, Can, Aldo+Cort Aldo+Can. Student’s t test reveals no statistical 
significance. 
 
Taken together these data assess that PA RBCs seemed not to be subjected to 
increased oxidative stress, nor Aldo seemed to induce any alteration in the main 
parameters representative of the oxidative status, such as GSSG, GSSP, and CA. 
 
3.2. Tyr-protein kinase and phosphatase assays  
To further assess RBCs membrane status from both HC and PA patients and after 
in vitro treatments, Tyr-protein kinases and phosphatases distribution and 
activation were analysed. Previous studies demonstrated that diamide-induced 
Tyr-P of membrane band 3 involved the combined action of two different Tyr-
kinases, Syk and Lyn, together with the counteracting activity of a Tyr-protein 
phosphatase, SHP2, responsible of the band 3 dephosphorylating process (Brunati 
et al., 2000; Bordin et al., 2002). Diamide, by oxidizing the catalytic cysteine 
residue of the Tyr-phosphatases, almost completely inhibited dephosphorylating 
process, thus evidencing phosphorylated residues. The differences showed in the 
band 3 Tyr-P level between HC and PA, as well as in the in vitro treatments, 
could be due to an imbalance between these two opposite activities. 
Membranes, from HC, PA and in vitro treated RBCs were analysed by Western 
blotting and revealed with anti-Syk, anti-SHP-2 or anti-P-Src antibodies. Nor Syk 
or SHP-2 resulted differently recruited to membranes (data not shown), indicating 
no constitutive alteration of the different membranes. Interestingly, anti-P-Src 
evidenced a net increase of the phosphorylated activated isoform of the Src family 
members in the PA group compared to HC (145±5% compared to 100±3%), and 
further confirmed in the in vitro experiments by Aldo addition (Table 3).  
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Samples 
pSrc (%) 
PTK Activity 
(%) 
PTP Activity 
(%) 
HC 100±3 100±2 100±4 
PA 145±5 * 115±3 * 103±5 
     
In
 v
it
ro
 
C 102±2 101±3 101±3 
2 nM Aldo 134±4 * 108±5 * 104±3 
5 nM Aldo 167±4 * 126±4 * 105±4 
5 µM Cort 104±3 103±2 104±4 
Aldo + Cort 109±5 107±4 103±2 
1 µM Can 101±3 101±3 99±5 
Aldo + Can 103±2 103±4 101±3 
 
Table 3. P-Src contents, protein tyrosin kinases (PTK) and protein tyrosin 
phosphatases (PTP) activity in HC, PA or in vitro treated RBCs. Fresh blood was 
collected from HC and PA and RBCs were isolated as described in Methods. For in vitro 
treatment, only blood from HC was utilized, and RBCs, were incubated at 37°C for 24 h 
in absence (C) or presence of 2 or 5 nM aldosterone (Aldo) or 5 µM cortisol (Cort) or 1 
µM canrenone (Can), alone or in association (Aldo+Cort or Aldo+Can), in charcoal-
stripped plasma to remove small molecular weight macromolecules such as steroid and 
peptide hormones. After incubation, RBCs underwent hemolysis in hypotonic buffer.  
P-Src content: RBCs membranes underwent Western blotting and were revealed with 
anti-P-Src or anti-actin antibody as loading control. Bands were scanned 
densitometrically. The values were obtained as the ratio percentage to the P-Src content 
of RBCs from HCs (chosen as arbitrary comparison units). The figure is representative of 
12 separate experiments. 
PTK and PTP activity: membranes were analyzed for PTK and PTP activity as 
described in Methods. The values were obtained as the ratio percentage to PTK or PTP 
activity of RBCs from HCs (chosen as arbitrary comparison units). The figure is 
representative of 12 separate experiments. 
* p<0.001, comparison of p-Src, PTK or PTP % of HC vs PA; for in vitro experiments 
comparison of C vs all other samples; Student’s t-test. 
 
 
When both Tyr-kinase and phosphatase assays were performed in membranes 
from RBC incubated in the absence of diamide, a 15% increase of the Tyr-kinase 
activity, but not of the Tyr-phosphatase counterpart, was substantiated in PA 
group, reaching the 25% in Aldo-treated RBCs (Table 3). When the same assay 
was performed in membrane from diamide-treated RBCs, PTK resulted similar if 
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not identical to that of diamide-untreated RBC (not shown), whereas PTPase 
activity was almost completely inhibited by diamide, as expected (not showon). 
This slight increase of the Tyr-kinase activity, however, was not sufficient to 
induce a net imbalance in the Tyr-phosphorylation process of membranes from 
RBCs not incubated with diamide, as indicated by the absence of phosphorylation 
in both PA and Aldo-treated RBCs, which remained similar to HC RBCs.  
 
3.3. Evaluation of the redox-related band 3 
aggregates formation 
To evidence if membrane band 3 aggregation was under redox regulation, we 
subjected membranes to Western blotting in both non reducing and reducing 
conditions. Results showed that membranes from HC RBC incubated with Aldo 
increasing concentrations contained increasing band 3 aggregates (Fig. 13) which 
were promptly and completely  reversed in the presence of β-mercaptoethanol, the 
reducing  effector. 
  
 
Figure 13. Band 3 HMWA contents in vitro treated RBCs. HC RBCs, isolated as 
described in Methods, were incubated at 37°C for 24 h in absence (C) or presence of 2 or 
5 nM aldosterone (Aldo) in charcoal-stripped plasma. After incubation, RBCs underwent 
hemolysis in hypotonic buffer. RBCs membranes underwent Western blotting in non-
reducing conditions (lane a, b and c) or in reducing conditions (addition of β-
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mercaptoethanol; lane d, e and f) and were revealed with anti-band 3 or anti-actin 
antibody as loading control. The figure is representative of 12 separate experiments.  
 
 
Similar results were also obtained when PA RBC membranes were analyzed, and 
the comparison among the different conditions were reported in Table 4. 
 
        
Samples 
Band 3 HMWA 
NR R 
HC 1.00±0.04 1.00±0.02 
PA 1.97±0.12 * 1.02±0.06 
    
In
 v
it
ro
 
C 1.02±0.03 0.99±0.04 
2 nM Aldo 1.32±0.19 * 1.04±0.03 
5 nM Aldo 1.78±0.15 * 0.98±0.05 
 
Table 4. Band 3 HMWA contents in HC, PA or in vitro treated RBCs. Fresh blood 
was collected from HC and PA and RBCs were isolated as described in Methods. For in 
vitro treatment, only blood from HC was utilized, and RBCs, were incubated at 37°C for 
24 h in absence (C) or presence of 2 or 5 nM aldosterone (Aldo) in charcoal-stripped 
plasma. After incubation, RBCs underwent hemolysis in hypotonic buffer. RBCs 
membranes underwent Western blotting in non-reducing conditions (NR) or in reducing 
conditions (R) and were revealed with anti-band 3 or anti-actin antibody as loading 
control. Bands were scanned densitometrically. Band 3 HMWA values were obtained as 
the ratio to the HMWA content of RBCs from HCs (chosen as arbitrary comparison 
units), respectively, in non-reducing or reducing conditions. The figure is representative 
of 12 separate experiments. 
* p<0.001, comparison of band 3 HMWA of HC vs PA and, for in vitro experiments, 
comparison of C vs all other samples, respectively in non-reducing or reducing 
conditions, Student’s t-test. 
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DISCUSSION 
 
MR activity has long been related to the genomic response occurring after half/an 
hour from Aldo addition and involving Aldo-MR shifting to the nucleus to 
regulate gene transcription. Recently, growing evidences of an early non-genomic 
response have been related to direct Aldo effects on protein kinases, Na+/H+ 
exchangers and NADPH oxidase (Dooley et al., 2012; Hayashi et al., 2008). In 
fact, beside the essential role of Aldo in regulating hydro/saline homeostasis, 
recent studies have emphasized its involvement in the occurrence of inflammatory 
status, both local (Hayashi et al., 2008) and general (Calò et al., 2004). Aldo 
promotes tissue inflammation, leading to fibrosis and tissue remodeling in the 
heart, vascular system, and kidney (Shibata and Fujita, 2012; Egido, 1996; Berl et 
al., 1978). It also contributes to generalized inflammatory status by activating 
circulating mononuclear cells, as shown by the Aldo-induced expression of PAI1 
and p22phox (Calò et al., 2004) and, non-genomically, by directly activating 
NADPH-oxidase dependent oxidative species production (Hayashi et al., 2008). 
We demonstrated that RBCs from PA patients display as similar membrane 
alterations to those previously observed in other inflammation diseases, such as 
endometriosis and PCOs (Bordin et al., 2010b; Donà et al., 2012), two clinical 
situations where Aldo or Aldo/PRA ratio are higher than in controls. These 
alterations can be observed in the presence of an adjunctive stress, such as that 
induced by diamide, which can trigger band 3 Tyr-P to a remarkably higher level 
in patients, as compared to HCs (Fig. 1). This could be due to an unbalance of the 
antithetic activities of Tyr-protein kinases and phosphatases, or to membrane 
reorganization, exposing band 3 target differently to the above activities. The 
higher HMWA content found in PA RBCs (Fig. 2) indicates a sensible alteration 
of the target band 3 and, hence, of the membranes, since band 3, as integral 
protein, is responsible for the interaction between the bilayer and the underlying 
cytoskeleton. 
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Similar results were obtained in vitro by incubating CS-PPP RBCs from HCs in 
the presence of Aldo, showing that a non-genomic effect of Aldo in RBCs is 
mediated by the classic MR, which was evidenced in RBCs cytosol. MR 
involvement in the Aldo-related signaling was further confirmed by the findings 
that both Can and Cort prevented Aldo-induced alterations. 
Moreover Aldo dose and time dependently increases band 3 HMWA formation 
and augments RBCs IgG binding, consistent with an involvement of Aldo in 
premature RBC aging. To date and to our knowledge, no evidence has been 
reported about a clear antagonistic effect of Cort in the non-genomic signaling of 
Aldo-MR. (Published in : Bordin et al., 2013) 
Further investigations regarding the possible role of Cort in RBCs from patients 
with PA also would be helpful in the comprehension of steroid hormone 
signaling. 
 
 
To completion of the previous study, we demonstrated the presence of MR in the 
RBC cytosol (Fig. 6), thus giving a clear explanation to the antagonistic/blocking 
effects of Cort or Can co-incubation with Aldo in in vitro experiments. To 
investigate the effective pathway involved, we further investigated cytosol where 
we found that, in non-activated conditions, such as in the absence of Aldo and 
other steroid hormones (CS-PPP), MR is mainly complexed in a multiprotein 
aggregate, which ensures it has the correct conformation for binding effectors. 
When Aldo is added, it binds to MR, causes it to break away from the complex, as 
shown by the shifting of the molecular weight of MR in the glycerol gradient, and 
induces it to form dimers (Fig. 7). Aldo-MR dimers have a short life-span, as 
shown by the time-dependent increase of MR destruction in low molecular weight 
fragments (Figs. 7 and 8) thus ensuring signal shutdown and sequestration of Aldo 
in the proteolysed fragments (data not shown), in a sort of Aldo scavenging from 
circulation.  
Concomitantly, in the membranes, Aldo induced alterations were mainly 
detectable after 24 h of incubation in a dose- and time-dependent manner (Figs. 4 
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and 5), and consisted of band 3 aggregation and circulating IgG binding (Bordin 
et al., 2013). 
 
When Aldo is replaced by Cort, MR shifted slightly from the gradient area of the 
MR complex in the early 30 min of incubation (data not shown), after which MR 
reconstituted its initial complex (Fig. 7). This is in line with the fact that Cort did 
not induce alterations in RBC membranes but, when added with Aldo, prevented 
Aldo-mediated alterations (Bordin et al., 2013). 
Can did not cause any alteration in the complex, but completely avoided Aldo-
induced disaggregation and alterations in membranes (Bordin et al., 2013). 
Interestingly, in both Aldo-MR dimer and MR-complex, MR binding is regulated 
by redox conditions, as shown by the differences in reducing and non-reducing 
conditions (compare Figs. 7 and 8). In addition, the observation that the anti-MR 
antibody used for the immunoprecipitation, recognizing the N-terminal region (aa. 
1-300) of the MR, did not bind to MR when dimerised or complexed, suggests 
that this region is involved in dimer/complex formation (Fig. 9). This was further 
confirmed by Cort inducing MR release but not dimerization. In this way, the N-
terminal region of Cort-MR remains free: a) to be recognized by the antibody; b) 
to re-associate with the multi-protein complex, by releasing Cort, thus maintaining 
the correct conformation for potential later Aldo binding. In addition, MR re-
association prevents MR degradation, which was only slightly higher than in 
controls, thus contributing to MR reserve maintenance. 
As determinant part of the complex, the chaperone protein HSP90 has a central 
role in the MR activation. Gelda, which binds to the N-terminal domain ATP 
binding site of HSP90 and inhibits the chaperone activity of the HSP90 (Stebbins 
et al., 1997), succeeded in releasing MR from the complex completely but 
prevented Aldo-induced MR dimerization, thus confirming that the multi-protein 
complex is fundamental in maintaining MR in the correct conformation for later 
Aldo binding. This was further demonstrated by the fact that when HC RBCs 
were pre-incubation with Gelda, Aldo failed to evoke membrane alterations 
leading to IgG binding (Fig. 10), thus confirming that intact complex is needed for 
the correct Aldo MR response. 
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HSP90 is known to be involved in cell proteostasis by chaperoning native proteins 
into multiprotein complex to prevent misfolding and turn over. HSP90 associates 
with a number of signaling proteins (Mjahed et al., 2012) ensuring their stability 
and correct functioning in the regulation of the programmed cell death. The 
involvement of cytosolic HSP90-multiprotein complex in the development of cell 
patho-physiology has been recently assessed in B-cell chronic lymphocytic 
leukemia where HSP90 association with Lyn's dysregulated expression, activity, 
and localization supported abnormal cell survival by inhibiting an early player of 
apoptotic signaling. (Contri et al., 2005; Zonta et al., 2014).  
 
 
Figure 14. MR regulation by Cort, Aldo, Can and HSP90 inhibitor. 
 
In conclusion, our data demonstrate that in human RBCs a genomic-like Aldo 
signaling involves MR activation, dimerization and proteolysis but avoids gene 
transcription and oxidative intermediates. This MR-mediated response involves 
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ligand specificity, with Aldo inducing MR activation leading to RBCs membrane 
alterations and IgG binding (Bordin et al., 2013) and Cort preventing MR 
activation. This different ligand-dependent recruitment of MR has not yet been 
demonstrated in other tissues where MR specificity for Aldo was tightly related to 
the expression of 11-beta-hydroxysteroid dehydrogenase 2, which transforms Cort 
to cortisone thus preventing MR inappropriate activation (Albiston et al., 1994). 
The evidence that Aldo-induced activation/dimerization is regulated by oxide-
reductive conditions and HSP90-chaperoned complex integrity may be also useful 
for the better comprehension of potential complications in PA.  
 
At last, due to the reported pro-oxidative effect of Aldo (Pu et al., 2003; Kotlyar et 
al., 2006; Patni et al., 2007; Yamaji et al., 2009; Calò et al., 2010; Stehr et al., 
2010), our investigations focuses on potential traces of oxidative intermediates 
generated by the Aldo-induced MR activation and acting at membrane level. 
The redox state of the cell was evaluated by assessing the contents of both 
cytosolic GSH and that of glutathionylated proteins (GSSP) in the absence or 
presence of diamide. In facts, as previously shown in other inflammatory diseases, 
diamide treatment enhances eventual pre-existent alterations of the cell membrane 
proteins, by inducing disulfide bond formations between GSH and the SH group 
of protein cysteine residues to form GS-SP. When GSH content was tested in 
cytosol or membranes from RBC previously incubated in the absence or presence 
of diamide, the addition of glutathione reductase, which should reduce disulfide 
and reconstituted the initial condition in the same extent in patients and in 
controls. 
 
The difference between the GSH content without and with diamide may be 
directly related to the oxidative state of membrane proteins (Bordin et al., 2010b). 
Neither GSSG nor GSSP were altered in either PA patients or in in vitro 
experiments with increasing concentrations of Aldo (Table 1), thus excluding an 
oxidative process involving glutathione-mediated processes in the Aldo-related 
alterations.  
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However, cells contain complex systems of multiple types of antioxidants, such as 
vitamins as well as enzymes such as catalase, superoxide dismutase and various 
peroxidases, all able to counteract specifically different forms of oxidative assault. 
To obviate the need to test each of the above anti-oxidants, we monitored a 
cytosolic protein, CA, which we demonstrated to be particularly sensitive to high 
oxidative status. In fact, we demonstrated that this enzyme, generally present in 
dimeric 60 kDa isomer, is particularly sensitive to oxidative-related 
transformation, yielding a 30 kDa isomer which is much more active than the 
larger one. CA activity is mainly and directly related to the amount of 30 kDa 
monomer available in the cellular compartment, as also demonstrated by diamide-
induced monomerization and activation (Fig. 12). CA activity and 
monomerization showed no differences between HC and PA groups, nor any 
alteration was detectable in in vitro experiments with increasing Aldo 
concentrations (Table 2), thus further confirming that Aldo did not induce 
membrane alterations through a common oxidative-related way, but through a 
different signaling pathway.  
 
To better understand membrane alterations inducing band 3 aggregation, we 
compared membranes in both reducing and non-reducing conditions. Whereas in 
non-reducing conditions band 3 aggregated mostly in PA RBCs as well as in Aldo 
treated cells, as previously demonstrated (part 1; Bordin et al., 2013), in reducing 
conditions band 3 HMWA content was almost completely identical both 
comparing HC and PA groups, and HC RBCs incubated in the presence of 
increasing Aldo concentrations. That no difference was detectable in membranes 
of patients or after Aldo treatment suggests that band 3 aggregation was 
dependent on the oxidation of SH-groups, since -mercaptoethanol, reducing 
effector used to induce reducing conditions, affects principally protein disulfide 
bonds. That this clusterization may be due to an oxidative process or membrane 
alterations, leading to band 3 aggregation, was at the basis of a successive 
cysteine auto-oxidation was not investigated and would be further addressed in 
forthcoming studies. Anyway, in the first case, it should be ruled out that Aldo-
MR signaling involves a “mediator”, able to oxidize band 3 cysteines, whereas, in 
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the second case, it triggers a “mediator” able to induce such membrane alterations 
that band 3 clusters thus leading to successive auto-oxidation. The common factor 
remains Aldo-MR activation as further demonstrated by the successive results. In 
facts, in in vitro experiments, when Aldo was added in association with Gelda, an 
inhibitor of the HSP90 protein, neither HMWA nor IgG binding was observed, 
thus confirming once more that Aldo effects were mediated by the activation of 
the cytosolic MR, which needs the association in the HSP90 multiprotein complex 
to be kept in the correct conformation for the eventual activation. 
 
In conclusion, we found that in PA RBCs Aldo is responsible for the membrane 
alterations leading to a potential premature removal of the cells from circulation. 
Aldo exerts its effect through the activation of the soluble MR complex, which 
participates in the modulation of the Aldo signaling through the possibility of 
being differently affected by other steroids or Aldo inhibitors (Can). In addition, 
membrane alterations are related to band 3 aggregation through disulfide bond 
formation, though no common parameter of oxidative assault was evidenced. 
Further studies are in progress to explore both nature and potential mediators of 
the Aldo-induced alterations in the band 3 dimer formation. 
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Other studies carried out during PhD program 
 
During my PhD I also collaborated with Professor Decio Armanini and his 
working group at Department of Medicine – Endocrinology (University of 
Padova),  participating in various projects. 
The oxidization processes, at the basis of my investigations, and their biological 
impacts were also evaluated in RBC from patients with other inflammatory 
diseases (polycystic ovary syndrome and endometriosis) and in other cells 
(spermatozoa).  
 
PCOs and Endometriosis 
Polycystic ovary syndrome (PCOs) and endometriosis are two different 
pathologies which I demonstrated to share a common denominator: an oxidative-
related increase in glutathionylation of membrane proteins with an enhanced band 
3 aggregates and Tyr-phosphorylation process (Donà et al., 2012; Andrisani et al., 
2014). 
 
Spermatozoa 
I began sperm investigations before my PhD training and occasionally I addressed 
again to better comprehend the involvement of ROS and oxidative assault in the 
membrane alterations and Tyr-phosphorylation. 
By the time-dependent evaluation of sperm ROS production as a simple method 
for rapid clinical estimation of the fertilizing ability of these cells, I evaluated 
different commercial buffers commonly used to induce sperm capacitation. This 
process, strictly related to membrane alterations and Tyr-phosphorylation of 
sperm head, would predispose sperm to the best conditions for the following 
intrauterine insemination (IUI) or in vitro fecundation (IVF), by far increasing 
reproductive success. After reporting what was the best medium for capacitating 
the highest number of cells and preventing time-dependent apoptosis (Andrisani et 
al., 2014), I investigated potential effectors able to ameliorate patients’ sperm by 
regulating endogenous ROS productions. I found that astaxanthin (Asta), a photo-
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protective red pigment synthesized by the microalgae and belonging to the 
carotenoid family, was able to perturb sperm membrane organization by inserting 
into the membrane bilayer without altering/scavenging superoxides. In this way, 
Asta may set free proteins involved in the following Tyr-phosphorylation process 
and related acrosome reaction, even in the absence of additional stimuli, such as 
ROS lipid peroxidation (Donà et al., 2013).  
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